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ABSTRACT 
 AMP-activated protein kinase (AMPK) is an energy-sensing enzyme that is 
activated when cellular energy is low and causes muscle and other cells to increase 
glucose uptake and fat oxidation, diminish lipid synthesis, and alter expression of various 
genes. AMPK activity is diminished in animals with the metabolic syndrome, though the 
mechanisms causing this reduction are unknown. To examine nutrient-induced changes 
in AMPK activity over time and factors that may regulate it, we compared rat muscle 
incubated with high glucose (HG) (30min-2h) and muscle of glucose-infused rats (3-8h) 
with appropriate controls. In addition to diminished AMPK activity (measured by the 
SAMS peptide assay) and phosphorylation of its activation loop at Thr
172
, we observed 
increased muscle glycogen, phosphorylation of AMPK’s α1/α2 subunit at Ser485/491, and 
PP2A activity, and decreased SIRT1 expression, all of which have been shown to 
diminish AMPK activity. Dysregulation of one or more of these factors could contribute 
to pathophysiological changes leading to metabolic syndrome associated disorders. 
 Since recent studies suggest phosphorylation at Ser
485/491 
may play an important 
role in AMPK inhibition, we sought to determine how phosphorylation of this site is 
regulated. We investigated whether insulin or diacylglycerol (DAG) signaling pathways 
  vii 
may be involved, since both are increased in at least one of the HG models. Akt and 
Protein Kinase (PK)D1 phosphorylated AMPK at Ser
485/491
 and diminished its activity in 
C2C12 myotubes, downstream of insulin and the DAG-mimetic PMA, respectively. 
Additionally, p-AMPK Ser
485/491
 was increased in muscle and liver of fed versus fasted 
mice and liver of diabetic mice. Our results suggest that Akt- and PKD1-mediated 
inhibition of AMPK via Ser
485/491
 phosphorylation may inhibit energy-metabolizing 
processes, while favoring energy-storing processes. Our results highlight the fact that 
phosphorylation of Ser
485/491 
can inhibit AMPK activity independent of changes in p-
AMPK Thr
172
, a measure which is often used as a readout of AMPK activity. We 
hypothesize that Akt-mediated inhibition of AMPK is an acute, physiological response to 
insulin, whereas PKD1-mediated inhibition may be associated with more chronic 
pathophysiological changes. Thus, PKD1 inhibition or prevention of Ser
485/491
 
phosphorylation may represent new strategies for therapeutic AMPK activation as 
treatment for the metabolic syndrome. 
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CHAPTER ONE 
Introduction and Overview 
Overview 
 The prevalence of worldwide obesity, type 2 diabetes (T2D), and the metabolic 
syndrome are increasing at an alarming rate. Insulin resistance (IR) in peripheral tissues 
(muscle, liver, and adipose) is a key pathological defect in T2D. Since skeletal muscle is 
responsible for 70-80% of insulin-stimulated glucose uptake [1], skeletal muscle IR is 
considered a critical pathological component of the metabolic syndrome and T2D [2]. 
Acute IR may be a normal or protective response of the cell to excess nutrients under 
physiological conditions, possibly a mechanism to reroute unneeded fuel to other parts of 
the body, or to prevent oxidative stress and glucotoxicity [3]. In this setting, normal 
insulin signaling resumes when nutrient levels return to normal. In contrast, chronic 
nutrient excess causes changes which are less easily reversible that prevent normal 
glucose uptake, thus causing hypergylcemia and hyperinsulinemia in the plasma, but 
glucose deprivation in the tissue. Additionally, more damaging secondary changes such 
as pancreatic -cell apoptosis, inflammation, oxidative stress, and vascular/endothelial 
dysfunction result [4]. The molecular sequence of events by which chronic exposure to 
excess nutrients (high glucose, lipids) impairs insulin signaling has been studied in detail, 
but remains incompletely understood. Hyperinsulinemia, inflammation, oxidative stress, 
ER stress, and the accumulation of toxic lipid derivatives, such as diacylglycerol (DAG) 
and ceramides, have all been implicated to contribute to the development of IR [1,5]. 
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Which of these factors is the primary cause, or whether it is a combination of them, 
remains under debate.  
 AMP-activated protein kinase (AMPK) is an energy sensing enzyme that plays a 
central role in nutrient sensing/insulin sensitivity. It is a heterotrimeric protein that is 
activated when energy levels are low (i.e., exercise or starvation) and signals to increase 
ATP generating processes and decrease ATP consuming processes. The consequences of 
its activation (mediated through a high AMP/ATP or ADP/ATP ratio and 
phosphorylation of AMPK Thr172) have been studied in detail. Pharmacological agents 
that indirectly activate AMPK by altering the cellular energy state (AMP/ATP ratio) are 
currently used in the clinic (i.e., Metformin, TZDs) and are of interest in drug 
development [6], as they prevent and/or reverse some of the pathologies of T2D. 
However, a direct modulator of AMPK has yet to make it to the clinic. 
 In contrast to the plethora of knowledge regarding AMPK activation, the 
mechanisms and consequences of AMPK downregulation below basal levels, which our 
lab has shown to occur early on in the setting of high nutrient induced IR, are less 
understood [7]. Notably, multiple animal models with a metabolic syndrome phenotype 
have decreased AMPK activity in muscle and liver [6,8-11], and loss of AMPK is 
detrimental in a number of metabolic challenges [9,12-16], such as diet-induced IR and 
obesity [17], calorie restriction [18], and exercise [19]. In addition, decreased AMPK 
activity in skeletal muscle [20] and adipose tissue [21,22] of humans with T2D or obesity 
has been reported. Although no causal inferences can be established in humans, 
dysfunction of AMPK may predispose obese individuals to a variety of metabolic 
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complications, including IR and T2D. The precise mechanism for the suppressed activity 
of AMPK is unknown; however, prolonged exposure to excess nutrients (glucose, 
branched chain amino acids (BCAA), and fatty acids (FA)) has been shown to cause 
diminished AMPK activity [7].  
 Our lab has previously shown that incubation of rat extensor digitorum longus 
muscle (EDL) with 25mM glucose for 1h suppresses AMPK activity, as evaluated by 
decreased phosphorylation of Thr
172
 on the “activation loop” of the  subunit, diminished 
phosphorylation of its downstream substrate ACC at Ser
79
 (a site only phosphorylated by 
AMPK), and also a reduction in kinase activity as measured by the SAMS peptide assay 
[7]. Many factors may contribute to the decrease in AMPK activity, such as reduced 
phosphorylation of AMPK Thr
172
 (either by reduced activity of upstream kinases or 
increased phosphatase activity), increased phosphorylation of 1/2AMPK Ser485/491, a 
site that is presumed to be inhibitory, changes in adenine nucleotide levels (decreased 
AMP/ATP ratio), a change in redox state, or other factors that may alter aspects of this 
pathway [23]. The overall aims of this work are (1) to determine the changes in AMPK 
activity and phosphorylation over time in skeletal muscle exposed to excess glucose (ex 
vivo incubation with glucose and in vivo glucose infusion) and factors that may contribute 
to its inhibition, (2) to investigate the upstream kinases responsible for phosphorylating 
AMPK at Ser
485/491
 phosphorylation and their contribution to diminishing AMPK activity 
and insulin sensitivity, and (3) to determine the regulation of AMPK Ser485/491 
phosphorylation in physiological (fasting/refeeding) and pathological (db/db mice) 
models of nutrient excess. 
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Type 2 Diabetes 
 T2D is a metabolic disease characterized by elevated blood glucose levels in the 
presence of peripheral insulin resistance. According to the International Diabetes 
Federation, more than 350 million people worldwide had diabetes in 2014, and it is 
projected that this number will rise to nearly 600 million by 2035 [24]. T2D is associated 
with a number of complications and co-morbidities, including cardiovascular disease, 
blindness, kidney failure, and lower limb amputation [24]. The number one risk factor for 
T2D is obesity, in which chronic nutrient overconsumption leads to hyperglycemia, 
insulin resistance, and impaired metabolic function. 
Insulin resistance 
 Insulin resistance is defined as the inability of a known quantity of exogenous or 
endogenous insulin to stimulate glucose uptake and utilization and suppress hepatic 
glucose production as much as it would in a healthy individual [25]. Since excess 
intracellular glucose causes cellular toxicity by a variety of mechanisms, insulin 
resistance is a protective mechanism to avoid this toxicity in environments of over-
nutrition. However, this protective mechanism leads to pathological changes in the 
setting of prolonged exposure to nutrient overload. In this state of chronic insulin 
resistance, reduced glucose uptake in muscle and adipose tissue, impaired suppression of 
hepatic gluconeogenesis, and impaired suppression of lipolysis lead to hyperglycemia, 
hyperinsulinemia, and hyperlipidemia. Initially, pancreatic β-cells compensate by 
secreting more insulin. Eventually, however, these cells become dysfunctional due to a 
combination of factors including endoplasmic reticulum (ER) stress, inflammation, and 
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oxidative stress [26]. This ultimately leads to decreased β-cell mass and inadequate 
insulin secretion, at which point exogenous insulin becomes necessary.  
 In a normally functioning muscle cell, insulin, which is a peptide hormone made 
in pancreatic β-cells and secreted in response to elevated blood glucose, binds to the 
insulin receptor, which is a transmembrane receptor tyrosine kinase [27]. Binding of 
insulin to the insulin receptor causes the autophosphorylation of the receptor on several 
tyrosine residues on the intracellular tyrosine kinase domain. These changes lead to the 
recruitment and phosphorylation of various substrate proteins, such as insulin receptor 
substrate 1 (IRS-1). Activated IRS-1 then recruits and activates phosphatidylinositol 3-
kinase (PI3K), which catalyzes the formation of phosphatidylinositol 3,4,5-trisphosphate 
(PIP3). PIP3 recruits 3-phosphoinositide-dependent kinase-1 (PDK-1) and Akt (also 
known as protein kinase B (PKB)) to the plasma membrane [27]. Akt is then activated by 
being phosphorylated at two sites: Thr
308
 by PDK-1 and Ser
473
 by mTOR complex 2 
(mTORC2); phosphorylation at both sites is required for full activation [28]. Akt 
phosphorylates Akt substrate of 160 kDa (AS160, also known as TBC1 domain family 
member 4 (TBC1D4)) and TBC1 domain family member 1 (TBC1D1), which inhibit Rab 
GTPase activity and promotes GTP binding to Rabs, thereby allowing glucose trasporter 
type 4 (GLUT4) translocation to the membrane and glucose uptake (See Figure 1.1 for a 
simplified insulin signaling diagram) [27]. Akt also has many other downstream 
substrates, including glycogen synthase kinase-3 (GSK-3). GSK-3 is inhibited by Akt 
phosphorylation, which leads to dephosphorylation and activation of glycogen synthase 
(GS) and a subsequent increase in muscle glycogen content. In an insulin resistant state, 
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phosphorylation and activation of Akt is often impaired, which prevents normal glucose 
uptake. Thus, diminished insulin-stimulated Akt phosphorylation is often used as an 
indicator of insulin resistance.  Activity of IRS-1 is often also diminished in IR due to 
inhibitory phosphorylation on serine residues as a consequence of protein kinase C (PKC) 
activation. 
 The molecular mechanisms responsible for insulin resistance are incompletely 
understood. Many proteins and biological pathways involved in metabolic homeostasis 
are dysregulated, and many factors, such as inflammation and oxidative and ER stress, 
are thought to play a role. The enzyme AMPK is of interest because it is not only 
inhibited in IR states, but its activation also has insulin sensitizing effects.  
 
Figure 1.1: Insulin signaling in skeletal muscle. 
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As described in the text, insulin binds to the insulin receptor, a transmembrane receptor 
tyrosine kinase, which activates IRS-1 and subsequently PI3K. This leads to activation of 
Akt by phosphorylation at two sites (Thr
308
 by PDK-1 and Ser
473
 by mTORC2). Akt 
signals to AS160 and TBC1D1 to stimulate GLUT4 translocation and increase glucose 
uptake and to GSK3 to increase glycogen synthesis. Adapted from [27]. 
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AMP-activated Protein Kinase (AMPK) 
Overview and Structure 
 AMPK is a phylogenetically conserved serine/threonine kinase that functions as a 
master metabolic regulator. It exists as a heterotrimer, consisting of a catalytic -subunit 
and regulatory β- and γ-subunits. Each subunit has multiple isoforms (1, 2, β1, β2, γ1, 
γ2, γ3), making a total of twelve possible heterotrimer combinations. Whether there are 
functional differences between the different isoforms remains unclear, however, some 
isoforms are tissue specific. For example, heterotrimers containing the 1 isoform 
predominate in liver and adipose tissue, whereas those containing 2 predominate in 
brain, heart, and skeletal muscle [29,30].  
 Activation of AMPK requires both an increase in the intracellular AMP:ATP ratio 
and phosphorylation of Thr
172
 on the “activation loop” [31] of the -subunit by one of its 
three upstream kinases: the tumor-suppressor liver kinase B1 (LKB1) [32,33], the 
calcium-dependent calcium/calmodulin-dependent protein kinase kinase β (CaMKKβ) 
[34], or transforming growth factor-β activated protein kinase-1 (TAK1) [35]. Although 
Thr
172
 on the α-subunit is regarded as the main phosphorylation/activation site, changes 
in AMPK activity have recently been observed in the absence of altered Thr
172
 
phosphorylation. As such, AMPK activity may be impacted by one of several other 
phosophorylation sites on AMPK with less defined functions [30]. One such site is 
Ser
485/491
 on the α1/α2 subunit, which will be discussed below in further detail. 
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 The  subunit contains four CBS domains (each pair is referred to as a Bateman 
domain) to which adenine nucleotides bind [36]. Three of the four CBS domains bind 
adenine nucleotides; site three primarily has AMP bound, however this can be replaced 
by ATP under specific conditions [37]. The other two binding domains can bind AMP, 
ADP, or ATP depending on their relative concentrations [36]. Under normal conditions, 
ATP is bound to these domains; however, when the AMP:ATP ratio is increased, AMP 
replaces ATP at the Bateman domains, causing an allosteric change that contributes to 
AMPK activation. This allosteric change makes AMPK a better substrate for its upstream 
kinases to phosphorylate it at Thr
172
 and inhibits dephosphorylation of this site by the 
protein phosphatases PP2A and PP2C [38,39]. The combination of allosteric activation 
and phosphorylation at Thr
172
 leads to a greater than 1000-fold increase in kinase activity 
in cell-free assays [40], although the changes under physiological conditions are likely 
much smaller [41]. Recently, it has been proposed that ADP, as well as AMP, may be 
able to activate AMPK by binding to the Bateman domains [42,43]. Whether this occurs 
under normal physiological conditions remains under debate, as AMP is a much more 
potent allosteric activator [41]. The structures of AMPK’s subunits are shown in Figure 
1.2.  
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Figure 1.2: AMPK subunits and their structural domains. 
AMPK’s catalytic α1/α2 subunit consists of a kinase domain, and autoinhibitory domain, 
a linker domain, and a C terminal domain, which includes a serine/threonine (ST) rich 
loop. Phosphorylation of Thr
172 
in the kinase domain contributes to enzyme activation, 
while phosphorylation of Ser
485/491
 of the ST loop is inhibitory.The β1/β2 subunits consist 
of a glycogen-binding domain (also known as carbohydrate binding motif (CBM)) and a 
C terminal domain that binds to the α and γ subunits. The γ1/γ2/γ3 subunits contain four 
CBS domains, which bind AMP, ADP, or ATP depending on their relative 
concentrations. Adapted from [44]  
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 Upon activation, AMPK phosphorylates its downstream targets, a main one being 
acetyl-CoA carboxylase (ACC) [45]. AMPK phosphorylates ACC at Ser
79
 (an inhibitory 
site), preventing the conversion of acetyl-CoA to malonyl CoA, which allows long-chain 
FA to enter the mitochondria for oxidation. Other downstream targets of AMPK include 
TSC2, which inhibits mTORC1 and protein synthesis [46]; HMG-CoA reductase, which 
leads to inhibition of cholesterol synthesis [47]; PGC1α, which stimulates mitochondrial 
biogenesis [48,49], and many others. See figure 1.3 for a broader list of AMPK substrates 
and their functions.  
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Figure 1.3: Downstream substrates of AMPK and their functions. 
AMPK phosphorylates many downstream substrates. As shown, AMPK activation has 
many effects on cellular functions, such as increasing fatty acid oxidation, mitochondrial 
biogenesis, autophagy, angiogenesis, and glycolysis, while inhibiting ROS production, 
cell growth, and protein and cholesterol synthesis. Reproduced from [50] 
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 AMPK activation has effects on a multitude of tissues (see Figure 1.4). In skeletal 
muscle, its activation stimulates glucose uptake, FA oxidation, GLUT4 translocation, and 
mitochondrial biogenesis, while inhibiting protein and glycogen synthesis [30]. Similarly, 
in cardiac muscle, AMPK activation stimulates glucose uptake, FA oxidation, and 
glycolysis [51]. AMPK stimulates glucose uptake and FA oxidation in liver, while 
inhibiting gluconeogenesis and cholesterol, FA, and protein synthesis. In adipose tissue, 
it stimulates FA oxidation and reduces FA synthesis and lipolysis [30]. AMPK inhibits 
insulin secretion from pancreatic β-cells [30], and it signals to increase food intake in the 
hypothalamus [52]. Nearly all of the physiological effects of peripheral AMPK activation 
would be beneficial for a patient with T2D. For this reason, pharmacological activation of 
AMPK has been a seemingly promising target for drug discovery and development 
during the past two decades.   
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Figure 1.4: Roles of AMP-activated protein kinase (AMPK) in the control of whole-body energy metabolism. 
Activation of AMPK (green lines) stimulates energy-generating pathways in several 
tissues while inhibiting (red lines) energy-consuming pathways. In skeletal muscle and 
heart, activation of AMPK increases glucose uptake and fatty acid oxidation. In the liver, 
AMPK activity inhibits fatty acid and cholesterol synthesis. Lipolysis and lipogenesis in 
adipose tissue are also reduced by AMPK activation. Activation of AMPK in pancreatic -
cells is associated with decreased insulin secretion. In the hypothalamus activation of 
AMPK increases food intake. [53]  
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AMPK Ser
485/491 
 As previously mentioned, recent data suggests that the Ser
485/491
 site on AMPK’s 
1/2 subunit may play an important role in modulating AMPK activity. 
Phosphorylation of this site has been shown to inhibit AMPK in several tissues, though 
its role in muscle or liver has not been investigated. Ser
485
 on the 1 subunit has been 
shown to be phosphorylated by Akt [54,55], protein kinase A (PKA) [56,57], or 
autophosphorylation [56] in various cell types and tissues, such as heart [54], adipocytes 
[57,58], and vascular smooth muscle cells [55]. Similarly, Ser
491
 of the 2 subunit can be 
phosphorylated by PKA [56,57], p70S6K [59], or autophosphorylation [60] in tissues 
such as adipocytes [57], hypothalamus [59], heart [54], and HEK293 cells [60], resulting 
in reduced AMPK activity. Although previous studies suggested that Ser
491
 is also an Akt 
phosphorylation site, a recent study by Hawley et al. showed that Akt does not 
phosphorylate Ser
491
 in a cell-free assay [60]. In heart, it has been shown that insulin and 
IGF-1 rapidly stimulate phosphorylation of this site through Akt, leading to a decrease in 
AMPK activity. In the hypothalamus, Dagon et al. [59] showed that p70S6K 
phosphorylates α2AMPK Ser491 to inhibit AMPK and decrease food intake. Some of 
these changes in serine phosphorylation correlate inversely with that of Thr
172
; however, 
in many instances, there seems to be discordance between the two phosphorylation sites.  
 Whether Ser
485/491
 phosphorylation plays a role in the inhibition of AMPK seen in 
diabetic models is unknown. Notably, recent studies suggest that phosphorylation of this 
site may be increased under conditions of excess nutrients. For example, it was shown 
that when the MIN6 cell line of pancreatic -cells were switched from low glucose 
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(3mM) culture medium to high glucose (25mM) for either 1h or overnight, 
phosphorylation of α1AMPK Ser485 was increased [61]. In this experiment, 
phosphorylation at this site was inversely correlated to phosphorylation of αAMPK 
Thr
172
.  
AMPK Activators 
 Numerous physiological, pharmacological, natural, and hormone activators of 
AMPK are known. Some of these are currently used clinically for the treatment of T2D. 
The following is a non-comprehensive list of some of the most established and newly 
identified AMPK activators that may have positive effects in patients with T2D, and their 
mechanisms of action, if known (Figure 1.5). A more thorough list of AMPK activators 
can be found in recent reviews by Steinberg et al. [30] and Fogarty et al.[62].  
Physiological 
Exercise and Calorie Restriction 
 Exercise and calorie restriction exert beneficial effects on metabolic health and 
decrease risk for a variety of diseases, including T2D and cardiovascular disease. Both 
exercise and caloric restriction are metabolic stresses that increase the AMP:ATP ratio in 
an organism’s cells, and thus can activate AMPK. Studies in the past two decades have 
revealed that AMPK is stimulated by muscle contractions in both rodents [63-67] and 
humans [68-70] and is a crucial enzyme through which exercise imparts many of its 
positive effects. ATP turnover in skeletal muscle is elevated over 100-fold during 
exercise [71], causing a rapid rise in AMP and ADP levels in an intensity-dependent 
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manner [71]. High-intensity muscle contractions preferentially activate 1-containing 
heterotrimers; while 2 activity is stimulated by low-intensity exercise and increases 
progressively with intensity [29]. 
 Although AMPK activation has not been proven to be the mechanism by which 
exercise exerts its positive metabolic effects, several studies have shown that 
pharmacological AMPK activation mimics the effects of endurance training (eg, 
increased FA oxidation, mitochondrial biogenesis) in rodents [72], suggesting that 
AMPK may mediate the effects of exercise. A recent study showed that AMPK β1/β2 
skeletal muscle knockout mice not only have a reduced exercise capacity, but also have 
reduced contraction-stimulated glucose uptake and skeletal muscle mitochondrial content 
[73]. Similarly, AMPKα1/α2 skeletal muscle knockout mice have reduced exercise 
tolerance, maximal force production, and fatigue resistance. However, in contrast to the 
β1/β2 knockout mice, these mice have reduced oxidative capacity, but not mitochondrial 
number [74]. These findings suggest that AMPK is, at least in part, responsible for 
exercise-induced stimulation of glucose uptake and mitochondrial biogenesis. 
Pharmacological 
AICAR 
 AICAR (5-aminoimidazole-4-carboxamide riboside) was the first compound 
identified to activate AMPK [75,76]. It is structurally similar to adenosine and, upon 
entering cells, is phosphorylated by adenosine kinase to become ZMP [75]. ZMP is an 
AMP analog that can bind to the CBS domains on AMPK’s -subunit to cause allosteric 
activation and allow for increased phosphorylation of Thr
172
. AICAR treatment has been 
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shown to prevent and/or reverse some aspects of the metabolic syndrome in animal 
models such as ob/ob mice [77], fa/fa rats [78,79], and rats fed a high fat diet [80]. For 
example, AICAR treatment improves glucose tolerance and whole-body glucose disposal 
and reduces hepatic glucose output and plasma triglyceride and FFA levels [77-80]. 
AICAR also induces expression of genes involved in oxidative metabolism and improves 
running endurance [81]. For these reasons, the World Anti-Doping Code banned its use 
by athletes in 2011 [82]. 
 Despite these promising effects in animal models, AICAR is unlikely to be used 
in the treatment of human T2D or metabolic syndrome due to poor bioavailability and a 
short half-life. Additionally, AICAR can mimic other actions of AMP to have AMPK-
independent effects, such as inhibition of the enzyme fructose-1,6-bisphosphatase 
(FBPase) [83] and stimulation of muscle gylcogen phosphorylase [84]. However, AICAR 
may be useful in treating humans with acute lymphoblastic leukemia [85,86] and cardiac 
ischemic injury [87,88]. Interestingly, another recently described AMPK activator, 
Compound 13, is taken up into cells and converted to the AMP analog Compound 2, 
which is a much more potent and specific activator of AMPK compared to ZMP [89]. 
Compounds of this series are being optimized for oral bioavailability and 
pharmacokinetics; however, their clinical utility remains to be seen. 
Biguanides 
 Metformin, which belongs to the biguanide family of insulin-sensitizing drugs, is 
currently the first-line oral therapy for T2D, according to national and international 
guidelines [90-93]. The biguanides also include phenformin, buformin, and the 
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antimalarial agent proguanil. This class of drugs originates from the French lilac plant, 
which has been used in folk medicine to treat diabetes for centuries, due to its glucose-
lowering properties [94,95]. Although phenformin and buformin are more potent insulin 
senstitizers than metformin, they also have a higher risk for unwanted side effects, 
namely lactic acidosis. For this reason, they were withdrawn from the market, leaving 
metformin as the only biguanide available for treatment of T2D. Within 12 weeks of 
receiving FDA approval in 1994, metformin became the most frequently prescribed oral 
anti-diabetic drug in the US [96], and it is currently prescribed to over 100 million 
patients worldwide [90]. Metformin reduces HbA1c by 1-2% in patients with T2D and 
reduces mortality compared to diet modifications alone [97]. In addition to its 
hypoglycemic effects, metformin has very few side effects, is weight neutral, and recent 
epidemiological studies suggest that patients taking metformin may have lower risks of 
cardiovascular disease [98] and certain types of cancer [99,100].  
 Since metformin was discovered before the use of targeted drug discovery 
techniques, for a long time its mechanism of action was not known, and it still is not fully 
understood. In 2001, Zhou et al. reported that metformin activates AMPK [101], and 
many studies since then have attributed metformin’s insulin-sensitizing actions to AMPK 
[102]. Metformin does not activate AMPK directly; instead, it has been shown to inhibit 
complex I of the mitochondrial respiratory chain [103], which promotes a switch from 
aerobic to anaerobic glycolysis, thus increasing the AMP:ATP ratio and promoting 
AMPK activation. This indirect mechanism is supported by the fact that metformin fails 
to activate AMPK in cell-free assays [104] and in cells expressing AMP-insensitive 
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(R531G) gamma2 variants [105]. Inhibition of hepatic gluconeogenesis is thought to be 
the primary means by which metformin exerts its effects on glucose homeostasis. It can 
also stimulate glucose uptake in adipose and skeletal muscle, although times and 
concentrations needed to stimulate AMPK and glucose uptake were much larger than 
would be found in vivo [101,106]. A recent study using liver-specific AMPK1/2 or 
LKB1 knockout mice brought into question the dependence of metformin’s effects on 
AMPK, since metformin treatment lowered blood glucose levels in both of these mouse 
models [107]. An even more recent study reported that metformin exerts its effects on the 
liver by antagonizing glucagon signaling through cAMP and PKA, independent of 
AMPK [108]. In contrast, mice with mutations in ACC1/2 that prevent phosphorylation 
and inactivation by AMPK, when made obese by high-fat feeding, are refractory to the 
lipid-lowering and insulin-sensitizing effects of metformin, suggesting that inhibitory 
phosphorylation of ACC by AMPK is essential for metformin-induced improvements in 
insulin sensitivity [109]. Despite these conflicting results, AMPK is likely an effecter of 
some of metformin’s insulin sensitizing effects, though further studies are needed to 
distinguish the AMPK-dependent from AMPK-independent effects.  
Thiazolidinediones 
 Thiazolidinediones (TZDs) are a class of insulin-sensitizing drugs, including 
rosiglitazone, pioglitazone, and troglitazone. Although their primary target is the nuclear 
hormone receptor peroxisome proliferator-activated receptor-γ (PPARγ), they are thought 
to exert some of their anti-diabetic effects through AMPK activation [110]. TZDs have 
been shown to rapidly stimulate AMPK and ACC phosphorylation in a variety of tissues, 
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including skeletal muscle [110,111] and liver [112]. Like metformin, they do so 
indirectly by inhibiting complex 1 of the mitochondrial respiratory chain to increase the 
cellular AMP:ATP ratio [105,110,113]. Additionally, TZDs may indirectly activate 
AMPK through the effects of PPARγ to stimulate adiponectin secretion (described in 
more detail below) [114,115].  
 In patients with T2D, TZDs improve insulin sensitivity in muscle, liver, and 
adipose, improve glycemic control (reduce HbA1c), enhance endothelial function, and 
reduce inflammation [116]. However, the main drawbacks of TZDs are that they cause 
weight gain (particularly subcutaneous adiposity), may increase risk of bladder cancer 
[117], and may worsen congestive heart failure, though they are not associated with 
increased mortality [116,118]. 
GLP-1 receptor agonists 
 Glucagon-like peptide-1 (GLP-1) is an incretin that is secreted from intestinal L-
cells following ingestion of food. GLP-1 stimulates insulin secretion in a glucose-
dependent manner, decreases pancreatic glucagon secretion, increases β-cell mass and 
insulin gene expression, stimulates satiety in the brain, and increases peripheral insulin 
sensitivity [119]. Based on these anti-diabetic actions, GLP-1 mimetics, such as exenatide 
and liraglutide, have been developed for the treatment of T2D. An alternative strategy 
that has been undertaken to increase GLP-1 levels is the development of DPP-4 
inhibitors, which prevent the inactivation of GLP-1 [120]. Recent studies have shown that 
these compounds, as well as endogenous GLP-1, can activate the AMPK pathway [121]. 
For example, exenatide treatment was shown to increase AMPK phosphorylation at 
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Thr172 in hepatocytes [121] and to decrease body weight, serum FFA and triglyceride 
levels, and reverse hepatic accumulation of lipids and inflammation in high-fat fed mice, 
while increasing AMPK mRNA and protein expression [122].  
A-769662 
 The first compound to be identified as a direct activator of AMPK was A-769662.  
This thienopyridone, identified by Abbott laboratories, activates AMPK in a similar 
manner to AMP; it causes allosteric activation and prevents dephosphorylation of Thr
172
 
[123-125]. Unlike AMP, however, A-769662 binds in a cleft between the kinase domain 
of the -subunit and the carbohydrate-binding domain of the β-subunit [126]. It is 
specific for the β1-isoform and requires βSer108 phosphorylation [125,127]. Treatment 
of ob/ob mice with this compound caused improvements in glucose homeostasis and lipid 
levels [123]. Despite these benefits on metabolic parameters, A-769662 is unlikely to be 
used to treat human metabolic syndrome due to its poor oral absorption and its reported 
AMPK-independent effects in which it can inhibit 26S proteasome activity and arrest 
cell-cycle progression [128]. However, A-769662 has utility as a research tool to further 
study the effects of AMPK activation. Recently, another compound referred to as 991, 
which is a cyclic benzimidazole derivative that binds to the same site as A-769662, was 
shown to be a much more potent AMPK activator [126]. Studies regarding the efficacy of 
this compound are in their infancy.  
Salicylate 
 Salicylates are natural substances produced by many plants to defend themselves 
against infections [129]. The medicinal use of salicylate was first described thousands of 
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years ago, when it was extracted from willow bark [130], making it one of the oldest 
medicines used by humans. It is often taken in the form of acetyl salicylate (trade name 
aspirin) or the diester salsalate, both of which are rapidly converted to salicylate in vivo 
[131,132]. It was recently reported that salicylate, but not aspirin, activates AMPK in 
HEK-293 cells at concentrations found in plasma of patients treated with high doses of 
aspirin [133]. Salicylate was determined to bind to the same site as A-769662 on the 1-
subunit based on findings that the ability of both compounds to activate AMPK is greatly 
diminished in complexes where the 2 rather than 1-subunit is expressed [133] and that 
the effects of both compounds are nearly abolished by an S108A mutation in 1 [133]. 
Further confirmation of a role for salicylate-induced AMPK activation in vivo was found 
when mice treated with salicylate had lower respiratory exchange ratios (RER) following 
food withdrawal, indicating a switch to fat oxidation [133]. However, these effects were 
not seen in 1 knockout mice [133].  
 These findings suggest that although salicylate is a less potent activator than A-
769662, it may have some utility in improving metabolic parameters in patients with 
T2D. Indeed, two randomized controlled trials showed that oral salsalate treatment 
decreased plasma glucose levels and insulin C-peptide and increased plasma adiponectin 
levels in obese young adults [134] and patients with impaired fasting glucose and/or 
impaired glucose tolerance [135]. Although these findings seem promising for the use of 
salicylate as an AMPK-mediated anti-diabetic treatment, further research is needed to 
fully define the role of AMPK in these outcomes. High fat-fed wild type and AMPK 1-
knockout mice treated with salicylate for two weeks both showed improved glucose 
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tolerance and reduced fasting glucose and insulin levels, suggesting that some of 
salicylate’s insulin-sensitizing effects are AMPK-independent [133]. 
PT1 and C24 
 PT1 is another small molecule compound that has recently been identified as a 
direct activator of AMPK [136]. Its mechanism of action is thought to be antagonism of 
the auto-inhibitory (residues 313-335) domain of the -subunit [136]. Treatment with 
PT1 dose-dependently increased AMPK activity and ACC phosphorylation in L6 
myotubes and HepG2 cells with no significant changes in the AMP:ATP ratios [136]. 
PT1 is not effective in vivo due to a poor pharmacokinetic profile, but structural 
optimization led to the discovery of the similar, but orally bioavailable compound C24 
[137,138]. C24 was shown to reduce glucose production and decrease triglyceride and 
cholesterol contents in hepatocytes [137]. Chronic oral treatment with C24 lowered blood 
glucose and lipid levels and improved glucose tolerance in db/db mice [137]. Whether 
C24 or a similar compound will make it to the clinic remains to be seen. 
Natural Compounds 
 
 Numerous naturally occurring compounds and phytochemicals have been shown 
to activate AMPK in vitro and in vivo and elicit metabolic benefits dependent on AMPK 
activation. 
Resveratrol 
 Resveratrol is a polyphenol found in red wine that has been suggested to mimic 
some of the effects of calorie restriction to increase lifespan. Treatment of high-fat fed 
animals with resveratrol causes improvements in insulin sensitivity and decreases 
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markers associated with aging [139]. Resveratrol has been shown to stimulate AMPK 
activity in multiple cell types, including hepatocytes [140-142], muscle cells [143,144], 
and neurons [145]. The mechanism by which resveratrol activates AMPK is thought to be 
an increase in AMP levels due to inhibition of the mitochondrial F1 ATPase [105,146]. 
Resveratrol treatment stimulates glucose uptake [144] and mitochondrial biogenesis 
[143] in muscle cells and stimulates mitochondrial biogenesis [140] and reduces lipid 
accumulation in liver [142]. The latter effect is blocked by a dominant negative AMPK, 
suggesting that it is AMPK-mediated. Further studies are required to determine how 
much of resveratrol’s effects are due to AMPK activation as opposed to activation of 
Sirtuin 1 (SIRT1), a redox-sensitive deacetylase whose activation has been shown to 
increase longevity. Of note, however, Ruderman et al. have shown that AMPK and 
SIRT1 can both regulate each other and share many common target molecules [147]. 
Rooibos 
 Rooibos (Aspalathus linearis) is a plant grown in South Africa that is popularly 
used in tea and has been shown to activate AMPK. Treatment of C2C12 myotubes with 
rooibos extract increases glucose uptake, mitochondrial activity, GLUT4 expression, and 
ATP production and reverses palmitate-induced insulin resistance [148]. In vivo, rooibos 
extract was reported to reduce serum cholesterol, triglyceride, and FFA concentrations in 
mice fed a high-fat diet [149]. Adipocyte size and triglyceride content were also reduced 
and hepatic steatosis was prevented. These metabolic improvements were attributed to 
AMPK activation in liver and adipose [149]. Similarly, ob/ob mice fed a diet containing 
0.1% rooibos extract had improved fasting blood glucose levels and improved glucose 
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tolerance compared to mice fed a control diet [150]. Furthermore, rooibos treatment 
decreased expression of gluconeogenic and lipogenic hepatic genes in these animals 
[150]. 
Berberine  
 Berberine is an isoquinoline alkaloid found in certain plants and has traditionally 
been used in Chinese and Korean cultures to treat fungal and bacterial infections, as well 
as T2D. Berberine has been shown to improve glucose tolerance [151], reduce body 
weight [151], increase expression of the insulin receptor (IR) and LDL receptor (LDLR) 
[152], lower total and LDL cholesterol [152], and reduce triglyceride levels [151,152] in 
several rodent models. Berberine has also been shown to lower blood glucose, 
triglyceride, and cholesterol levels to nearly the same degree as metformin [153]. It has 
been shown to potently activate AMPK in skeletal muscle [154], hepatocytes [155], and 
adipose tissue [156,157], although some of its anti-diabetic effects are likely mediated 
through AMPK-independent mechanisms, such as DPP-4 inhibition [158] and 
enhancement of SOD activity [159]. Like metformin and TZDs, berberine is thought to 
activate AMPK by inhibiting complex I of the mitochondrial respiratory chain, thus 
increasing the AMP:ATP ratio [105,160,161]. It has also been shown to increase 
adiponectin expression, which may contribute to both AMPK-dependent and independent 
effects [162].  
-lipoic acid 
 The short-chain fatty acid -lipoic acid is an essential cofactor for mitochondrial 
respiration and a powerful antioxidant and has been shown to activate AMPK in skeletal 
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muscle [7,163], heart [164], and endothelium [165]. It also inhibits AMPK signaling in 
the hypothalamus [166], thus reducing food intake. It has been shown to improve insulin 
sensitivity in obese rodents [167] and to reduce insulin secretion and -cell growth [168]. 
Furthermore, ex vivo incubation of rat skeletal muscle with -lipoic acid prevents high 
glucose- or leucine-induced impairments in insulin signaling [7], skeletal muscle lipid 
accumulation, and hepatic steatosis in obesity [167], Shen et al. showed that the 
mechanism by which -lipoic acid activates AMPK is through CaMKK-mediated 
phosphorylation of Thr172 [169]. They reported that the selective inhibitor of CaMKK 
STO-609 prevented -lipoic acid-stimulated AMPK activation and subsequent ACC 
phosphorylation. Alpha-lipoic acid has also been reported to have beneficial effects on 
diabetic neuropathy, although whether AMPK is also involved in mediating these effects 
is unknown [170,171]. 
Hormones 
 In addition to the exogenous pharmacological and natural compounds that can 
activate AMPK, there also exist endogenous hormones that can activate AMPK and elicit 
many of the same anti-diabetic effects. 
Leptin 
 Leptin is a hormone made and secreted by adipocytes that acts on the brain to 
regulate food intake and body weight. It can also act directly and indirectly on peripheral 
tissues, as almost all tissues express the leptin receptor.[172] Leptin increases the 
AMP:ATP ratio in skeletal muscle, thus activating AMPK and stimulating fatty acid 
oxidation [173]. This activation occurs only in 2-containing heterotrimers [174], 
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although the reason for this isoform specificity is not known. In addition to directly 
acting on skeletal muscle to activate AMPK, leptin can also indirectly stimulate AMPK 
in muscle via -adrenergic signaling from the CNS [175]. This activation is more 
delayed and requires the melanocortin 4 (MC4) receptor, since intracerebroventricular 
(ICV) administration of an MC4 receptor antagonist prevents CNS-mediated activation of 
skeletal muscle AMPK by leptin [175]. In contrast to its effects in skeletal muscle, leptin 
inhibits AMPK in the hypothalamus to inhibit food intake [52,176]. Yang et al. reported 
that it does so indirectly via a mechanism involving release of an opioid from a cell 
different from that in which AMPK is located [177].  However,it was recently reported 
that AMPK inhibition via phosphorylation of Ser
491
 on its 2-subunit by p70S6 kinase is 
required to mediate leptin’s anorectic effects [59].  
Adiponectin 
 This circulating hormone acts through its two receptors (adipoR1 and adipoR2) 
expressed in tissues such as adipose and skeletal muscle to regulate glucose levels and 
stimulate fatty acid oxidation [178] [179]. Adiponectin levels are reduced in obese 
humans and animals [180]. AMPK activation by adiponectin is dependent on signaling 
through AdipoR1 [181] and requires the adaptor protein, phosphotyrosine interaction, PH 
domain and leucine zipper containing 1 (APPL1) [182]. Purified adiponectin from human 
plasma potently activates AMPK activity in C2C12 myotubes [183], and adiponectin’s 
ability to suppress hepatic glucose output has been shown to be AMPK-dependent [184]. 
Adiponectin over-expression has been shown to reduce body weight, improve insulin 
sensitivity, and increase FA oxidation in various rodent models of genetic and diet-
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induced obesity [185-188]. Interestingly, adiponectin trimers and hexamers, but not high-
molecular-weight forms, stimulate food intake through AMPK activation in the 
hypothalamus [189]. 
Interleukin-6 
 Interleukin-6 (IL-6) is a pro-inflammatory cytokine that is elevated in obesity 
[190]. It is also produced and released from muscle during exercise to increase circulating 
levels almost 100-fold [191]. Interestingly, in obesity, IL-6 is associated with insulin 
resistance, whereas during exercise, it may enhance glucose uptake via AMPK activation. 
IL-6 increases muscle glucose uptake through an AMPK-dependent mechanism in 
cultured cells [192], rodents [192,193], and humans [194]. These effects of IL-6 are 
additive to those of insulin in stimulating glucose uptake [195]. However, some studies 
have shown that these effects are only seen at super-physiological concentrations [195]. 
AMPK activity is diminished in muscle and adipose tissue of IL-6 knockout mice, and 
exercise-stimulated AMPK activity is diminished in these mice [190,193]. Kelly et al. 
showed that IL-6 activates AMPK by increasing the concentration of cAMP and, 
secondarily, the AMP:ATP ratio [192]. 
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Figure 1.5: Physiological, pharmacological, natural, and hormonal activators of AMPK:  
As discussed in the text, there are many known activators of AMPK. This non-
comprehensive list highlights many of the well-established and newly discovered AMPK 
activators that have positive effects on T2D. Many activators activate AMPK via an 
increased AMP:ATP ratio (shown in red), causing AMP to bind to the γ-subunit. 
However, a subset of compounds stimulate AMPK activation via other mechanisms, such 
as binding directly to the -subunit (shown in green), stimulating phosphorylation of 
Thr172 through CaMKKβ (orange), or binding directly to the β-subunit (blue). The 
mechanism by which rooibos activates AMPK is not known. AICAR is phosphorylated 
to ZMP, an analog of AMP that can activate AMPK via the γ-subunit. [53]  
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Protein Kinase C 
 Protein kinase C is a family of lipid-sensitive serine/threonine kinases that are 
involved in many cellular signaling pathways. The structurally related isoforms are 
broken into three main categories based on sequence homology and modes of activation. 
The conventional (cPKC) isoforms (α, βI, βII, and γ) are activated by both DAG and 
Ca
2+; the novel (nPKC) isoforms (δ, ε, θ, and η) are DAG-sensitive but don’t require 
Ca
2+
; and the atypical (aPKC) isoforms (ζ and ι/λ) are activated by 3-phosphoinositide-
dependent kinase-1 (PDK1) or the toxic lipid derivative ceramide [196]. Many studies 
have reported that increased activation of various conventional and novel PKC isoforms 
is associated with the IR caused by chronic glucose or lipid oversupply (which causes 
DAG accumulation). Figure 1.6 shows the structures of the different families of PKC 
isoforms.  
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Figure 1.6: Structural domains of conventional, novel, and atypical families of PKC isoforms. 
All PKC isoforms consist of an N-terminal regulatory domain and a C-terminal catalytic 
domain. Conventional and novel isoforms contain C1A/B domains that bind DAG or 
phorbol esters, such as PMA. The atypical PKCs contain a C1 domain that binds PIP3 and 
ceramide, but not DAG or PMA. The conventional and novel isoforms also contain a C2 
domain, which binds calcium in the conventional isoforms, but not the novel isoforms 
since they lack critically positioned calcium-coordinating acidic residues. Reproduced 
from [197].  
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 Since DAG is located at the plasma membrane or other intracellular membranes, 
such as the endoplasmic reticulum (ER), PKCs translocate to these membranes during 
activation. Thus, membrane localization is often used as a measure of PKC activation. 
Rats fed a high-fat diet have higher proportions of membrane-associated PKCθ, ε, and δ 
in skeletal muscle, which correlate with increased muscle triglyceride and DAG content 
and insulin resistance [198]. Obese Zucker rats have increased DAG content, PKC 
activity, and PKCε and θ membrane localization compared to lean controls [199]. 
Genetically modified mice lacking certain PKC isoforms have improved glucose 
homeostasis, supporting a causal role for PKCs in IR [200,201]. For example, PKCβ 
knockout mice have slightly lower blood glucose and plasma insulin levels and enhanced 
2-deoxy-D-glucose (2-DOG) uptake in adipose tissue and muscle [201]. Mice lacking 
PKCθ are protected from IR following a 5-hour lipid infusion, whereas their wild-type 
counterparts show reductions in skeletal muscle glucose uptake and diminished IRS-1-
associated PI3K activity [200]. In humans, Itani et al. showed that DAG mass and 
PKCβII and θ membrane association are increased in skeletal muscle following a 6 hour 
lipid infusion [202]. A reduction in insulin-stimulated glucose disposal was also reported.  
In contrast to the conventional and novel PKC isoforms, atypical PKCζ and λ/ι 
have been shown to play a positive role in insulin-stimulated glucose uptake [203,204]. 
PDK-1, which is activated by insulin downstream of PI3K and phosphorylates Akt at 
Thr
308
, also phosphorylates and activates these PKC isoforms. The atypical PKCs then 
associate with GLUT4 vesicles and help mediate their translocation to the membrane to 
increase glucose uptake. To further confirm their importance in mediating glucose 
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uptake, mice lacking PKCλ in skeletal muscle are insulin resistant and dyslipidemic 
[205]. Atypical PKC activity is diminished in muscle and adipose tissue of humans with 
obesity and T2D [206,207]. However, activity of these isoforms is conserved in livers of 
humans with T2D, where it may have deleterious effects by increasing hepatic lipid and 
cytokine production [208]. Thus, inhibition of atypical PKC isoforms may represent a 
potential treatment strategy for IR or T2D if targeted selectively to the liver; whereas 
activation of atypical PKCs seems to improve insulin sensitivity in skeletal muscle and 
adipose tissue.  
 Despite the multitude of studies linking increased conventional and novel PKC 
activation with IR, the mechanistic relationship is incompletely understood. What is well 
known is that PKCs can inhibit IRS-1 through phosphorylation on serine residues. This 
prevents normal tyrosine phosphorylation of IRS-1 in response to insulin and subsequent 
downstream insulin signaling (See Figure 1.7) [209]. Other proposed mechanisms by 
which aberrant PKC activation could cause IR include the internalization and degradation 
of the insulin receptor, which is associated with prolonged PKC activation in NIH 3T3 
fibroblasts [210]. Altered PKC expression is also associated with diminished IRS-1 
expression in MCF7 breast cancer cells [211], muscle of obese humans [212] and adipose 
tissue of fat-fed rats [213]. Additional mechanisms could involve inhibition of the insulin 
receptor, IRS-1 or Akt through downstream effectors of PKCs, such as the mitogen-
activated protein kinases (MAPK) or c-Jun N-terminal kinase (JNK). 
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Figure 1.7: Normal and impaired insulin signaling pathways in skeletal muscle. 
During normal insulin signaling (A), insulin binds to the insulin receptor, which 
subsequently activates IRS1 and PI3K. Downstream signaling causes translocation of 
GLUT4 vesicles to the plasma membrane, which allows for the transport of glucose into 
the cell. One mechanism by which insulin signaling can be impaired (B) is through the 
accumulation of DAG, which leads to PKC activation and inhibitory phosphorylation of 
IRS1 on serine residues. In this case, GLUT4 vesicles do not translocate to the plasma 
membrane and glucose is not transported into the cell. Adapted from [214].  
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 Ido et al. [215] showed that incubation of human umbilical vein endothelial cells 
(HUVECs) with the AMPK activator AICAR prevented both high glucose induced DAG 
accumulation and impairment of insulin-stimulated Akt phosphorylation. This suggests 
that activation of AMPK may prevent aberrant PKC activation. Whether a reciprocal 
relationship exists whereby PKC activation directly or indirectly contributes to AMPK 
inhibition in response to excess nutrients is not known. Interestingly, Tsuchiya et al. 
recently showed that the PKC activator phorbol 12-myristate 13-acetate (PMA), which 
is a DAG mimetic, diminishes AMPK α2 activity in cardiac myocytes [216]. The 
mechanism behind this is not yet known. 
Protein Kinase D 
Overview and Structure 
 Protein kinase D (PKD) was first discovered in 1994. It was initially name PKCµ 
and classified as an atypical PKC [217]; however, it was later determined to be 
structurally and functionally distinct from the other PKC isoforms and was reclassified as 
a member of the Ca
2+
/calmodulin-dependent kinase (CaMK) family of serine/threonine 
kinases based on sequence and substrate homology [218]. Since then, two other PKD 
isoforms (PKD2 and PKD3) have been discovered, with the original one now referred to 
as PKD1. PKD1 is a 918 amino acid protein that is made up of an N-terminal regulatory 
domain, which consists of cysteine-rich, zinc-finger like motifs and an autoinhibitory 
pleckstrin-homology domain, and a C-terminal catalytic domain. DAG can bind to the 
cysteine-rich domains, which activates PKD in vitro. When activated, PKD1 undergoes 
transphosphorylation by novel PKCs at Ser
744/748
 of the activation loop and 
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autophosphorylation of Ser
916
 at the C terminus (See Figure 1.8). Thus, PKD can be 
activated either downstream of, or in parallel with PKC. In addition to DAG and PKC, 
PKD can be activated by other stimuli, such as G protein–coupled receptor agonists (eg, 
bombesin, vasopressin, bradykinin and endothelin-1 (ET1)) and oxidative stress [218].  
 
 
 
Figure 1.8: Structure of PKD1. 
PKD1 contains two cysteine-rich domains (C1a and C1b), which bind DAG or PMA, a 
pleckstrin homology domain, and a kinase domain. During activation, PKD1 is 
phosphorylated on Ser
744/748
 of the activation loop by novel PKCs and is 
autophosphorylation at Ser
916
. Reproduced from [219]  
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Functions 
 PKDs are involved in a wide variety of cellular functions, including signal 
transduction, membrane trafficking, and cell survival, migration, differentiation, and 
proliferation (See figures 1.9 and 1.10) [220]. PKD is activated by oxidative stress (in 
which phospholipase D1 (PLD1) and phosphatidic acid phosphatase (PAP)‐catalyse 
DAG synthesis) and promotes cell survival.  It does so by activating a cytoplasmic 
inhibitor of nuclear factor kappa-B kinase (IKK)α/IKKβ/NF-κB essential modulator 
(NEMO) complex, which causes Iκb degradation and NF‐κB nuclear translocation. 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF‐κB) then 
upregulates expression of the mitochondrial antioxidant MnSOD, which removes toxic 
reactive oxygen species (ROS). 
 PKD1 can also regulate transcription by acting as a class IIa histone deacetylase 
(HDAC) kinase. Phosphorylation of HDAC5 causes it to dissociate from the transcription 
factor myocyte enhancer factor 2 (MEF2), thus allowing MEF2 to upregulate many 
muscle-specific and metabolic genes. This is particularly relevant in cardiac muscle, 
since PKD1 has been shown to play a role in cardiac hypertrophy [218,221]. PKD1 
expression and activation are increased in humans and animals with heart failure 
[218,222]. Furthermore, mice with cardiac-specific deletion of PKD1 are protected from 
cardiac hypertrophy and fibrosis in response to pressure overload (thoracic aortic 
constriction) and chronic adrenergic and angiotensin II stimulation [223]. Conversely, 
transgenic mice expressing a constitutively active PKD1 mutant in heart have cardiac 
hypertrophy, followed by ventricular chamber dilation, wall thinning, and a marked 
  
39 
deterioration of contractile function [224]. These data suggest that PKD1 activation is 
sufficient to cause pathological cardiac remodeling.  
 In skeletal muscle, PKD1 activation has been shown to be involved in adaptations 
to acute exercise through HDAC5 phosphorylation [225]. Interestingly, AMPK also 
phosphorylates HDAC5 in response to exercise, again leading to derepression of MEF2 
[226]. Thus, both of these proteins promote the formation of slow-twitch, oxidative (type 
I) muscle fibers, which increases the capacity for aerobic exercise. It was recently shown 
that genetic deletion of PKD1 in type I muscle fibers causes susceptibility to fatigue 
[225]. However, AMPK activation also upregulates slow-twitch-fiber contractile genes 
such as peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC-1α), 
which stimulates mitochondrial biogenesis and oxidative metabolism [227]; PKD1 
overexpression does not induce these changes [225].  
 More recently, McGee et al. [228] found that expression of constitutively active 
PKD1 in C2C12 myoblasts resulted in increased glycolytic capacity and a modest 
increase in glucose oxidation. However, they found no effects on basal oxygen 
consumption rate, extracellular acidification rate, mitochondrial function, or palmitate 
oxidation. Interestingly, PKD1 has been shown to play a positive role in GLUT4 
translocation and contraction-stimulated glucose uptake in cardiac myocytes [229]. In a 
related study, Steinbusch et al. [230] showed that overexpression of either AMPK or 
PKD1 could prevent loss of insulin-stimulated glucose uptake due to high palmitate or 
insulin exposure in cardiac myocytes. However, overexpression of AMPK also restored 
insulin-signaling through Akt, while PKD1 overexpression did not. These data suggest 
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that some, but not all, functions of AMK and PKD1 may be redundant. In this case, there 
may be a need for the two proteins to have mechanisms by which they can negatively 
regulate eachother to keep their overlapping effects in check. 
 
 
 
Figure 1.9: Functions of PKD1 
PKD1 can be activated by a number of of signaling molecules which lead the the 
accumulation of DAG and/or activation of novel PKC isoforms. As shown, PKD1 
activation leads to many downstream responses including proliferation, differentiation, 
transformation, motility, invasion, migration, protein transport, membrane trafficking, 
apoptosis, cell survival, immune responses, and crosstalk to other signaling pathways. 
Adapted from [231]. 
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Figure 1.10: PKD1 Signaling Pathways 
PKD1 is involved in many signaling pathways in the cell. The diagram shows the 
involvement of PKD1 signlaing in (i) modulation of signaling pathways, (ii) regulation of 
class IIa HDAC, (iii) oxidative stress response, and (iv) membrane or protein trafficking. 
Reproduced from [231] 
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Overall Aims 
The overall aims of this work are: 
(1) To determine the changes in AMPK activity and phosphorylation over time in skeletal 
muscle exposed to excess glucose (ex vivo incubation with glucose and in vivo glucose 
infusion) and factors that may contribute to its inhibition.  
(2) To investigate the upstream kinases responsible for phosphorylating AMPK at 
Ser
485/491
 phosphorylation and their contribution to diminishing AMPK activity and 
insulin sensitivity. 
 (A) To determine whether insulin signaling phosphorylates and inhibits AMPK 
 activity in skeletal muscle. 
 (B) To determine whether protein kinase C (PKC) signaling phosphorylates and 
 inhibits AMPK activity in skeletal muscle. 
(3) To determine the regulation of AMPK Ser485/491 phosphorylation in physiological 
(fasting/refeeding) and pathological (db/db mice) models of nutrient excess 
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CHAPTER TWO: Materials and Methods 
Materials 
 C2C12 cells were purchased from ATCC (Manassas, VA). DMEM, Penicillin-
Streptomycin (P/S), fetal bovine serum (FBS) and horse serum (HS) were from 
Invitrogen (Grand Island, NY). D-(+)-Glucose solution, 45%, and insulin were obtained 
from Sigma-Aldrich (St. Louis, MO). Primary antibodies for Acetyl-CoA carboxylase 
(ACC), AMPK, phospho-AMPKα (Thr172), phospho-AMPKα1/α2 (Ser485/491), phospho-
PKD (Ser
916
), PKD, phospho-PKC (pan) (βII Ser660), phospho-PKCδ/θ (Ser643/676) , 
phospho-(Ser) PKC Substrate, phosphor-(Ser/Thr) PKD substrate, phospho-mTOR 
(Ser
2448
), mTOR, phospho-p70S6K (Thr
389
), phospho-Akt (Ser
473
), and Akt antibodies, as 
well as secondary horseradish peroxidase (HRP)-linked antibodies were purchased from 
Cell Signaling Technology (Danvers, MA). Phospho-ACC (Ser
79
) antibody was from 
Upstate/Millipore (Temecula, CA). Anti-β-actin was purchased from Sigma-Aldrich (St. 
Louis, MO). AMPKα1 and α2 antibodies used for immunoprecipitation were purchased 
from Santa Cruz Biotechnology, Inc. SAMS peptide was purchased from Abcam 
(Cambridge, MA) and [γ-32P] ATP was from Perkin-Elmer (Boston, MA). See Table 2.1 
for comprehensive list of antibodies used. 
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Antibody Dilution Source 
Predicted 
Molecular 
Weight Incubation Supplier 
Catalog 
number 
Phospho-AMPKα1 
(Ser485)/AMPKα2 
(Ser491)  1:1000 Rabbit 62 kDa 4°C O/N 
Cell 
Signaling 4185 
Phospho-AMPKα 
(Thr172) 1:1000 Rabbit 62 kDa 4°C O/N 
Cell 
Signaling 2531 
AMPKα 1:1000 Rabbit 62 kDa 4°C O/N 
Cell 
Signaling 2532 
AMPKα1 (for IP) 1:100 goat 62 kDa 4°C O/N Santa Cruz sc-19128 
AMPKα2 1 (for IP) 1:100 goat 62 kDa 4°C O/N Santa Cruz sc-19131 
phospho-ACC 
(Ser79) 1:1000 Rabbit 280 kDa 4°C O/N 
EMD 
Millipore 07-303 
ACC 1:1000 Rabbit 280 kDa 4°C O/N 
Cell 
Signaling 9272 
Phospho-Akt 
(Ser473) 1:1000 Rabbit 60 kDa 4°C O/N 
Cell 
Signaling 9271 
Akt 1:1000 Rabbit 60 kDa 4°C O/N 
Cell 
Signaling 9272 
Phospho-
PKD/PKCμ 
(Ser916) 1:1000 Rabbit 115 kDa 4°C O/N 
Cell 
Signaling 2051 
Phospho-
PKD/PKCμ 
(Ser744/748)  1:1000 Rabbit 115 kDa 4°C O/N 
Cell 
Signaling 2054 
PKD/PKCμ 1:1000 Rabbit 115 kDa 4°C O/N 
Cell 
Signaling 2052 
Phospho-(Ser/Thr) 
PKD Substrate  1:1000 Rabbit Many 4°C O/N 
Cell 
Signaling 4381 
Phospho-PKC (pan) 
(βII Ser660)  1:1000 Rabbit 
78, 80, 82, 85 
kDa 4°C O/N 
Cell 
Signaling 9371 
Phospho-(Ser) PKC 
Substrate  1:1000 Rabbit Many 4°C O/N 
Cell 
Signaling 2261 
β-actin 1:10,000 Mouse 42 kDa 4°C O/N 
Sigma 
Aldrich A5441 
Phospho-mTOR 
(Ser2448) 1:1000 Rabbit 289 kDa 4°C O/N 
Cell 
Signaling 2971 
mTOR 1:1000 Rabbit 289 kDa 4°C O/N 
Cell 
Signaling 2972 
GAPDH 1:1000 Rabbit 37 kDa 4°C O/N Santa Cruz Sc-25778 
Phospho-PKCδ/θ 
(Ser643/676) 1:1000 Rabbit 78 kDa 4°C O/N 
Cell 
Signaling 9376 
Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 1:1000 Rabbit 44, 42 kDa 4°C O/N 
Cell 
Signaling 9101 
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Phospho-SAPK/JNK 
(Thr183/Tyr185)  1:1000 Rabbit 54, 46 kDa 4°C O/N 
Cell 
Signaling 9251 
Phospho-IRS-1 
(Ser636/639) 1:1000 Rabbit 180 kDa 4°C O/N 
Cell 
Signaling 2388 
SIRT1 (SIR2)  1:1000 Rabbit 110 kDa 4°C O/N Millipore 07-131 
CaM kinase kinase 1:1000 Mouse 68 kDa 4°C O/N 
BD 
Transductio
n 610544 
 
Table 2.1: List of Antibodies used.  
Table 2.1 lists the primary antibodies used in these studies, as well as the dilutions, 
sources, predicted molecular weights, incubation conditions, suppliers, and catalog 
numbers. 
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Cell culture 
 C2C12 myoblasts were cultured in normal glucose (5.5 mM) DMEM 
supplemented with 10% fetal bovine serum (FBS), 1% glutamine, and 1% 
penicillin/streptomycin (P/S). Media was replaced every 24-48 h and cells were passaged 
upon reaching 80-90% confluence. At 80-90% confluence they were differentiated into 
myotubes in DMEM supplemented with 2% horse serum (HS) and 1% P/S. Glucose and 
FBS-free DMEM, supplemented with 1% P/S and glucose at a final concentration of 5.5 
mM, was used for all experimental incubations. 
Cell lysate preparation 
 Cells were washed once on ice with Dulbecco’s PBS, lysed in buffer containing 
20 mM Tris-HCl - pH 7.5, 150mM NaCl, 1mM Na2EDTA, 1% triton, 2.5mM sodium 
pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4, 1µg/ml leupeptin, 1x 
phosphatase inhibitor cocktail 3 (Sigma), and 1x protease inhibitor cocktail containing 
0.5 mM EDTA (Thermo Fisher Scientici), and removed from wells using a cell scraper 
with a polyethylene copolymer blade (Fisher Scientific). Cell debris was removed by 
centrifugation at 13,200 g for 10 minutes at 4°C, and the supernatant was removed and 
stored at –80°C until analysis. Protein concentration was assessed by the bicinchoninic 
acid method (BCA; Pierce Biotechnology, Inc., Rockford, IL). 
SDS-PAGE Western blot analysis 
 Protein expression and phosphorylation were determined in 10-30μg of protein 
lysate using SDS-PAGE gel electrophoresis and immunoblotting. Following transfer onto 
a polyvinylidene difluoride membrane, membranes were blocked in Tris-buffered saline 
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(pH 7.5) containing 0.05% Tween-20 (v/v;TBST) and 5% non-fat dry milk (w/v) for 1h 
at room temperature, followed by incubation in primary antibodies (dilution as indicated 
in table 2.1) at 4˚C overnight. After washing, membranes were incubated in a secondary 
antibody conjugated to horseradish peroxidase at a 1:5,000 dilution for 1h at room 
temperature. Bands were visualized using enhanced chemiluminescence solution (ECL; 
Pierce Biotechnology, Inc., Rockford, IL), and densitometry was performed with Scion 
Image software. 
AMPK activity assay 
 AMPK activity was assessed as previously described [7,67]. Briefly, AMPK α1 or 
α2 was immunoprecipitated from 500 μg of protein from cell lysates by incubation at 4˚C 
overnight on a roller mixer using AMPK α1 or α2-specific antibodies (1:80) and protein 
A/G agarose beads (1:10; Santa Cruz Biotechnology, Inc). Following several washes, 
activity was measured in the presence of 200 μM AMP and 80 μM [γ-32P] ATP (2 μCi) 
using 200 μM SAMS peptide (Abcam) as a substrate. Label incorporation into the SAMS 
peptide was quantified using a LabLogic (Brandon, FL) scintillation counter. 
Cell-free in vitro phosphorylation assay 
 Recombinant proteins were purchased from EMD Millipore (Billerica, MA) 
(AMPK) and Enzo Life Sciences (Farmington, NY) (PKD1 and Akt). Recombinant 
α2AMPK/β1/γ1 complex was incubated with recombinant Akt or PKD1 in 50 mM Na-
HEPES, 5 mM MgCl2, 500 μM ATP, 1 mM DTT for 30 min at 30°C. 
Animal studies 
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 Protocols for animal use were reviewed and approved by the Institutional Animal 
Care and Use Committee of Boston University Medical Center and were in accordance 
with National Institutes of Health guidelines. Animals were maintained on a 12:12-h 
light-dark cycle in a temperature-controlled (19–21°C) room and were fed standard chow 
and water ad libitum, unless otherwise noted. 
Experimental animals 
 Male Sprague-Dawley rats weighing 55–65 g were purchased from Charles River 
Breeding Laboratories (Wilmington, MA). They were maintained on a 12:12-h light-dark 
cycle in a temperature-controlled (19-21°C) room and were fed Teklad Global 18% 
Protein Rodent Diet (Harlan, Madison, WI) and water ad libitum. Muscles were removed 
from rats anesthetized with pentobarbital (6mg/100g BW). For glucose infusion studies, 
adult male Wistar rats (Animal Resources Centre, Perth, Australia) were communally 
housed in temperature controlled (22 ± 0.5°C) room on a 12:12-h light–dark cycle. Rats 
were fed ad libitum a standard chow diet (Rat Maintenance Diet; Gordon Specialty 
Feeds, Sydney, Australia). After a 1 week acclimatization period, cannulae were inserted 
into both jugular veins. 
Muscle incubations 
 Male Sprague-Dawley rats weighing 55–65 g were purchased from Charles River 
Breeding Laboratories (Wilmington, MA). Following an overnight fast, they were 
anesthetized with pentobarbital (60 mg / kg body weight), and extensor digitorum longus 
(EDL) muscles were removed for incubation. After removal, muscles were first 
equilibrated for 20 min at 37°C in oxygenated Krebs-Henseleit solution (95% O2/5% 
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CO2) containing 5.5 mM glucose, then were transferred to 25mM glucose (or other 
treatment condition, as indicated). Following incubations muscles were snap-frozen in 
liquid nitrogen, and stored at -80°C until analysis. 
 
 
 
 
Figure 2.1: Schematic of EDL incubation procedure.  
Extensor digitorum longus (EDL) muscles are extracted from anesthetized male Sprague-
Dawley rats (50-65g) and tied onto metal clips to keep the muscles extended. Muscles are 
equilibrated for 20 min at 37°C in oxygenated Krebs-Henseleit solution (95% O2/5% 
CO2) containing 5.5 mM glucose, and then transferred to another tube containing 25mM 
glucose (or other treatment, as indicated). Following incubations muscles were snap-
frozen in liquid nitrogen, and stored at -80°C until analysis. 
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Glucose Infusion 
 Glucose infusion was carried out as described previously [11]. Briefly, seven days 
after cannulation surgery, rats were randomly divided into treatment groups.  After a 
basal blood sample (600l) was taken, a 50% (w/v) glucose solution was infused for 0, 3, 
5 or 8h using a peristaltic roller pump (101U/R; Watson-Marlow, Falmouth, UK). Blood 
samples were taken every 30min and the glucose infusion rate was altered to maintain a 
blood glucose concentration of 11mM (~16-17mM plasma glucose). Following infusion, 
red gastrocnemius was collected, frozen, and stored at -80°C until homogenization.  
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Figure 2.2: Schematic illustrating glucose infusion procedure. 
Timing of experimental procedures is shown in (A), starting with cannulation of jugular 
veins, followed by a 7 day recovery, and the infusion of glucose for 3-8h. Example image 
showing cannulated rat during glucose infusion (B). Image reproduced from 
(http://www.tasmc.org.il/sites/en/Research/Tech-Transfer/Pages/Basic-Research-
Loboratory.aspx). Representative measurements of blood glucose and plasma insulin 
levels over time during glucose infusion (C) adapted from [232]. 
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Fast/Re-feed studies 
 C57BL/6 male mice were purchased from Charles River Breeding Laboratories 
(Wilmington, MA). Food was removed at approximately 4PM, and mice were starved 
overnight for 18 h. The next morning, half were sacrificed at 10AM by isoflourane and 
cervical dislocation, while the other group was re-fed for 2h with standard chow before 
being sacrificed. Muscle and liver were removed, frozen in liquid nitrogen, and stored at -
80°C until analysis. 
db/db mice 
 Male db/db and db/+ control mice were purchased from Charles River Breeding 
Laboratories (Wilmington, MA). Bodyweights and fasting blood glucose were measured 
weekly beginning at 9 weeks of age. Mice were sacrificed after 4 consecutive weeks of 
elevated blood glucose in the db/db mice compared to db/+ controls. Mice were 
sacrificed using isoflourane and cervical dislocation. Muscle and liver were removed, 
frozen in liquid nitrogen, and stored at -80°C until analysis. 
Other analyses 
 Protein concentrations were determined with the bicinchoninic acid (BCA) 
reagent (Pierce, Rockford, IL) using bovine serum albumin as the standard. ATP, AMP, 
ADP, and phosphocreatine were measured spectrophotometrically as described 
previously [7,233]. Lactate and pyruvate were determined spectrophotometrically using 
lactate dehydrogenase and NAD [7]. NAD and NADH were measured as described by 
Fulco et al [234]. Muscle glycogen content was determined using the phenol-sulfuric acid 
reaction [235]. 
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Statistical analysis 
 Results are reported as means ± standard error of the mean (SEM). All data were 
interval/ratio and normally distributed, which allowed for the use of parametric analyses. 
Statistical significance was determined by a two-tailed unpaired Student’s t-tests when 
comparing two experimental groups or conditions. For comparisons of three or more 
experimental groups, a one-way ANOVA was performed to determine whether there was 
a statistical difference in the means of the groups. If p<0.05 for the ANOVA, Tukey’s 
post-hoc test was used to determine whether there were differences between individual 
treatment groups. For repeated measures, such as the measurements of mouse body 
weight for db/+ and db/db mice over time, a two-way repeated measures ANOVA was 
used to determine whether the independent variables (genotype and time) affect the 
dependent variable (body weight), and whether there was an interaction effect of the 
independent variables. If p<0.05 by two-way repeated measures ANOVA, a Bonferroni 
post-test was performed to determine whether body weight differed between genotypes at 
each timepoint. A level of p<0.05 was considered statistically significant. N values are 
indicated for individual experiments. Graphpad Prism 5 was used for all statistical 
analyses. 
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CHAPTER THREE: Mechanisms of AMPK inhibition in response to high glucose 
Introduction 
 It has long been appreciated that nutrient excess leads to insulin resistance in 
many tissues [7,215,233,236-238]. In a recent study [7], our lab compared the events 
associated with insulin resistance in rat extensor digitorum longus (EDL) muscles 
incubated with a high concentration of glucose (25 vs. 5.5mM) or a normal glucose 
concentration (5.5mM) with added leucine (100 or 200μM) for 1h. The results strongly 
suggested that elevated concentrations of glucose or leucine cause insulin resistance by a 
common mechanism. Thus, both a high concentration of glucose and glucose plus leucine 
diminished AMPK activity and phosphorylation at Thr
172
 and increased mTOR/p70S6K 
phosphorylation. Treatment with the mTOR inhibitor rapamycin did not affect AMPK 
phosphorylation; however, incubation with two distinct AMPK activators, AICAR and 
alpha lipoic acid, prevented both the insulin resistance (impaired insulin-stimulated Akt 
phosphorylation) and mTOR/p70S6K phosphorylation. These results suggest that the 
decrease in AMPK activity is responsible, at least in part, for the glucose- and leucine-
induced increases in mTOR activation and insulin resistance. In contrast, the factors 
responsible for the decrease in AMPK activity and whether AMPK is inhibited further 
with more prolonged exposure to these nutrients have not been determined.  
 To examine these questions, we evaluated whether several factors that have been 
shown to decrease AMPK activity in other settings are altered in the aforementioned 
EDL model in response to excess glucose for 30min-2h. Additionally, we assessed 
whether the same factors were changed in vivo in rats in which AMPK activity was 
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diminished by a 3-8h glucose infusion that produced hyperglycemia, hyperinsulinemia, 
and insulin resistance. One factor examined was phosphorylation of Ser
485/491
 on 
AMPK’s α-subunit, an event that has been linked to the acute inhibition of AMPK by 
insulin within minutes in various tissues [54,58,239] and to the inhibition of 
hypothalamic AMPK by leptin [59]. Another was the upregulation of protein phosphatase 
2A (PP2A), which has been shown to mediate the deactivation of AMPK in rodent aorta 
following the infusion of palmitate [240]. We also measured muscle glycogen content, 
since glycogen has been shown to inhibit AMPK in cell-free conditions by binding to the 
glycogen-binding domain (GBD) of its β-subunit [241]. Finally, we related diminished 
AMPK activity in muscle to decreases in the activity of SIRT1 and factors that regulate 
it. As shown by a number of groups [141,147,242,243], the activation and 
downregulation of SIRT1, a histone-protein deacetylase, typically parallels that of 
AMPK.  
 Intriguingly, the results revealed that all of these putative regulatory factors were 
altered by hyperglycemia in the incubated EDL and in muscle of the glucose-infused rats. 
However, the timing of the changes varied with the model, such that the initial decrease 
in AMPK activity generally preceded the changes in its putative regulators in the 
incubated muscle but not in muscle of the glucose-infused rat. Increased glycogen 
content was the only change temporally associated with the initial decrease in AMPK 
activity in the muscles incubated with high glucose or leucine, suggesting that increased 
cellular energy in the form of glycogen may be the initiating factor leading to AMPK 
inhibition by excess nutrients. 
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Results 
Incubation of EDL with 25mM glucose decreased AMPK Thr
172
 and ACC Ser
79
 
phosphorylation and AMPK activity over time (30min-2h) 
Time-course studies revealed that incubation of the EDL with 25 vs. 5.5mM 
glucose decreased the phosphorylation of AMPK at Thr
172
 by 40% at 30min, 50% at 
60min, and 60% after 2h (Figure 3.1A). An almost identical pattern was observed when 
the activity of α2 AMPK, which is the dominant isoform in skeletal muscle was measured 
using the SAMS peptide assay (Figure 3.1D). In contrast, activity of α1 AMPK was 
unchanged, indicating that the effect was isoform specific. Finally, the decrease in p-
ACC Ser
79
, which is only phosphorylated by AMPK (Figure 3.1B), paralleled that of α2 
AMPK activity. The subsequent studies examined changes in factors that may mediate 
this downregulation of AMPK.  
Incubation of EDL with high glucose for 1 or 2h increased phosphorylation of AMPK 
Ser
485/491 
 Incubation of the EDL with a high glucose (25 vs. 5.5mM glucose) medium 
increased the inhibitory phosphorylation on AMPK at Ser485/491 by 250% and 200% at 
1 and 2h, respectively (Figure 3.1C). As already noted, no insulin was added to the 
medium.  
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Figure 3.1: Incubation of EDL with 25mM glucose diminishes AMPK Thr172 phosphorylation, ACC Ser79 
phosphorylation, and α2 AMPK activity, and increases AMPK Ser485/491 phosphorylation 
EDL muscles were incubated in Krebs-Henseleit solution containing 25 mM glucose for 
0.5, 1, and 2h. Phosphorylation of AMPK Thr
172
 (A), ACC Ser
79
 (B), AMPK Ser
485/491
 
(C) were measured by western blot and AMPK activity (D) was determined using the 
SAMS peptide assay. Results are means + SE (n = 6). *P < 0.05 relative to 0.5h 
incubation with 5.5 mM glucose. [244] 
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SIRT1 and factors that activate it were diminished in EDL following 2h of incubation 
with 25mM glucose 
SIRT1 protein expression (Figure 3.2A) and the ratio of nicotinamide adenine 
dinucleotide oxidized/reduced forms (NAD/NADH) (Figure 3.2C) were decreased by 
more than 2-fold at 2h when the concentration of glucose was increased from 5.5 to 
25mM. Both tended to decrease at earlier time points, but the differences were not 
statistically significant. Additionally, the activity of Nicotinamide 
phosphoribosyltransferase (NAMPT) (Figure 3.2B), a SIRT1 activator, was 50% lower in 
muscle incubated with 25mM glucose both at 1 and 2h, and the concentration of lactate 
and the lactate/pyruvate ratio were increased at both 1 and 2h (Table 3.1).  
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Fig. 3.2: Incubation of muscle in 25mM diminishes SIRT1 protein abundance, NAMPT activity, and 
NAD/NADH ratio after 1 or 2h. 
EDL were incubated with 25 mM glucose for 0.5, 1, or 2h. Western blot analysis 
and quantification of representative blots are shown. SIRT1 protein expression (A) 
NAMPT activity (B) and NAD/NADH (C) were determined as described in the methods 
section. Results are means + SE (n=6). *P < 0.05 compared to incubation with 5.5 mM 
glucose at each timepoint. [244]  
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 Lactate 
(µmol/mg) 
Pyruvate 
(µmol/mg) 
Lac/pyruv 
(µmol/mg) 
5.5 mM 
Glucose 
(1 h) 
13±3 1.3±0.1 10.0±2.0 
25 mM 
Glucose 
(30 
min) 
17±2 1.6±0.1 10.6±3.0 
25 mM 
Glucose 
(1 h) 
31±4* 2.0±0.3* 15.5±2.0 
25 mM 
Glucose
(2 h) 
33±5 2.1±0.4 15.8±2.0 
 
Table 3.1: Effects of high glucose on lactate and pyruvate. 
Data are means ± SEM (n+4-5/group). Lactate and pyruvate are expressed as µmol/mg 
muscle. *P < 0.05 relative to 30 min incubation with 5.5mM glucose [244]  
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Cellular energy state was unchanged in EDL incubated in 25mM glucose for 30min-2h 
In search for additional factors responsible for the decrease in AMPK 
phosphorylation caused by a high glucose concentration, we assessed cellular energy 
state. In keeping with previous observations [243], we found no differences in tissue 
concentrations of ATP, ADP, AMP or CrP in muscles incubated with 25 vs. 5.5mM 
glucose for 30min, 1h, or 2h (Table 3.2).  
 
 ATP 
(nmol/mg) 
AMP 
(nmol/mg) 
ADP 
(nmol/mg) 
CP 
(nmol/mg) 
5.5 mM 
Glucose
(1 h) 
3.9±0.04 0.06±0.003 0.60±0.04 15.0±4.0 
25 mM 
Glucose
(30 
min) 
3.7±0.02 0.05±0.001 0.50±0.02 13.0±2.0 
25 mM 
Glucose
(1 h) 
3.9±0.06 0.04±0.001 0.55±0.04 14.0±1.7 
25 mM 
Glucose
(2 h) 
3.8±0.05 0.04±0.002 0.60±0.05 13.5±2.0 
 
Table 3.2: Effects of high glucose on adenine nucleotides and creatine phosphate: 
Data are means ± SEM (n=4-5/group). Nucleotide values are expressed as nmol/mg 
muscle. [244]  
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Muscle glycogen content was increased in EDL incubated with 25mM glucose for 30min 
and 1h, while phosphorylation of GSK3β was unchanged 
Since glycogen has been shown to inhibit AMPK by associating with the CBD of 
the β-subunit [241], we measured muscle glycogen content following a 30 or 60 min 
incubation in 25 vs. 5.5mM glucose. We found that muscle glycogen was significantly 
increased at both timepoints, suggesting that glycogen may be responsible for the early 
and sustained inhibition of AMPK (Figure 3.3A). Activation of another known regulator, 
GSK3β, which has been shown to inhibit catabolic activity of AMPK by associating with 
the β-subunit and phosphorylating it at Thr479 of the α-subunit [245], was unchanged 
(Figure 3.3B) at all timepoints measured. 
 
Figure 3.3: Incubation with elevated glucose levels increases muscle glycogen content at 30 min and 1h.  
Glycogen content was measured in EDL muscles incubated for 0.5 or 1h (A) or 0.5, 1, or 
2h (B) in media containing 5.5 or 25 mM glucose. Muscle lysates were analyzed P-
GSK3β Ser9 (B) by western blot. Results show quantification of western blots by 
densitometry. Results are means + SE (n = 4-6). *P <0.05 compared to incubation with 
5.5 mM glucose at each timepoint. [244] 
  
63 
PP2A activity was increased in EDL incubated in 25mM glucose for 2h 
PP2A is a major protein serine/threonine phosphatase that regulates AMPK, 
among other molecules in mammalian cells [246-248]. As shown in Figure 3.4A, 
incubation with 25 vs. 5.5mM glucose increased PP2A activity by 1.7-fold; however, as 
with SIRT1, this change was only observed at the 2h time point.  
 
 
 
 
Figure 3.4: Incubation with elevated glucose levels and in vivo glucose infusion increases PP2A activity at 2h (ex 
vivo) or 8h (in vivo). 
EDL muscles incubated for 0.5, 1, or 2h in media containing 5.5 or 25 mM 
glucose (A) and red gastrocnemius muscles from rats infused with glucose for 0, 3, 5, or 
8h (B) were analyzed for PP2A activity as described in the methods section. Results are 
means + SE (n = 4-6). *P <0.05 compared to incubation with 5.5 mM glucose at each 
timepoint (A) or the 0h group for infusions (B). [244]  
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Infusion of glucose in vivo caused similar changes in AMPK and its potential regulators 
as EDL incubation with 25mM glucose, but with differences in timing 
 To determine whether the effects of glucose observed in the incubated EDL also 
occurred in vivo and in the presence of insulin, rats were infused with 50% glucose for 0, 
3, 5 or 8h at a rate adjusted to maintain plasma glucose concentration at 16-17mM. The 
plasma insulin level was 250μU/L during the infusion vs. 50μU/L prior to its start. In the 
red gastrocnemius (RG) muscle, the glucose infusion decreased both AMPK Thr
172
 
phosphorylation (Figure 3.5A) and AMPKα2 activity (by the SAMS peptide assay, 
Figure 3.5C) with a significant change observed at 5h. Interestingly, this was followed by 
a secondary increase in AMPK activity, something we have not observed in previous 
studies [232,249]. In keeping with these findings, the phosphorylation of ACC also was 
only significantly decreased at 5h (Figure 3.5D), although it is somewhat diminished at 3 
and 8h of infusion. In contrast, the increase in phosphorylation of AMPK at Ser
485/491
 
(Figure 3.5B) and the decreases in SIRT1 protein (Figure 3.6A), NAD/NADH (Figure 
3.6B), NAMPT activity (Figure 3.6C) and lactate/pyruvate ratio (Figure 3.6D), which 
occurred after the decrease in AMPK-Thr
172
 in the incubated EDL, took place at the same 
time (5h) and were maintained at 8h. Only the increase in PP2A activity (Figure 3.4B) 
was a later event (observed at 8h), as it was in the EDL incubated with a high glucose 
medium (Figure 3.4A).  
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Figure 3.5: Glucose infusion decreases AMPK Thr172 phosphorylation and α2 AMPK activity, and increases 
AMPK Ser485/491 phosphorylation in red gastrocnemius muscle. 
AMPK Thr
172
 (A) and AMPK Ser
485/491
 (B) and ACC Ser
79
 (D) phosphorylation were 
analyzed by western blot. α2 AMPK activity (C) was measured using the SAMS peptide 
assay as described in the methods section. Data are means ± SEM. n = 4–6 rats per group, 
P < 0.05 vs. 0h group. [244]  
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Figure 3.6: Glucose infusion diminishes SIRT1 abundance (A), NAD/NADH ratio (B), and NAMPT activity (C), 
and increases lactate/pyruvate ratio (D) in RG muscles.  
Red gastrocnemius muscles from rats infused with glucose for 0, 3, 5, or 8h were 
analyzed for SIRT1 protein expression (A) NAD/NADH ratio (B) NAMPT activity (C) 
and lactate/pyruvate (D). Data are means ± SEM. N = 4–6 rats per group, *P < 0.05 vs. 
0h group. [244]  
  
67 
Discussion 
 The biological relevance of AMPK activation, as well as how such regulation 
occurs, has been well described [30,62,147,227,250-252]. In contrast, less is known about 
the factors that contribute to AMPK inhibition and its biological effects. Our lab 
previously showed that incubation of rat EDL muscle for 1h in a high glucose (25mM) 
medium decreased AMPK activity and impaired insulin signaling (Akt phosphorylation) 
compared to EDL incubated in a normoglycemic medium (5.5mM). In addition, we 
found that all of the changes, including increases in mTOR/p70S6K phosphorylation and 
protein synthesis, in addition to the insulin resistance, could be prevented by co-
incubation with the AMPK activator AICAR. In the present studies, we investigated the 
effects of high glucose (25mM) over time (30min-2h) on AMPK activation and several 
factors that could modulate its activity, including serine phosphorylation at Ser
485/491 
and 
changes in SIRT1 and PP2A. We also sought to determine whether similar changes in 
these parameters occur in muscle in vivo, during a glucose infusion that increased plasma 
insulin as well as glucose. 
 We found that incubation of the EDL with 25mM glucose led to a 50% decrease 
in AMPK activity within 30min and an additional 50% reduction by 2h, as evidenced by 
decreases in both its phosphorylation at Thr
172
 and SAMS peptide phosphorylation. 
Interestingly, the later decreases in AMPK activity in these muscles were associated with 
increased phosphorylation of AMPK at Ser
485/491
 and changes in NAMPT and redox state 
at 1h, and alterations in SIRT1 expression (decreased) and PP2A activity (increased) at 
2h. Similarly, in vivo, infusion of glucose at a rate that maintained plasma levels at 16-
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17mM and increased plasma insulin 30-fold diminished AMPK activity and its 
phosphorylation at Thr
172
 at 5h. In contrast to the findings in the incubated EDL, changes 
in Ser
485/491 
phosphorylation, SIRT1 abundance, NAMPT activity, and redox state were 
observed concurrently. Only PP2A activation was a later event (8h). These findings raise 
several fundamental questions: (1) by what mechanism does excess glucose lead to the 
initial decrease in AMPK activity in the EDL, (2) what is the physiological significance 
of the later decreases in AMPK activity and the changes in its putative regulators, and (3) 
why does the temporal sequence of events differ between incubated muscle and muscle 
from rats infused with glucose in vivo despite similar changes in all of the above-
mentioned parameters?  
 To our surprise, in the incubated EDL, increases in most putative downregulators 
of AMPK activity occurred after, rather than before the initial decrease in AMPK activity 
(30min). Increased muscle glycogen content was the only regulatory factor we found to 
be changed at this early timepoint (Figure 3.3). Previous studies have shown that AMPK 
activation is lower in glycogen loaded versus depleted muscles in response to contraction 
[253] or AICAR [254] in rodents or in response to exercise in humans [255]. 
 Furthermore, glycogen was recently shown to directly inhibit AMPK in a cell-free 
system by binding to the GBD of its β-subunit, thus causing an allosteric change that 
inhibits its phosphorylation at Thr
172
 [241]. Although further studies are required to 
determine whether glycogen is responsible for the initial inhibition of AMPK in our 
muscle incubation model, this data is consistent with the hypothesis of Mcbride et al. 
[241] that AMPK is sensitive not only to changes in immediately available cellular 
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energy in the form of AMP and ATP (which were unchanged in our studies (Table 3.2)), 
but also to energy reserves in the form of glycogen. Despite the significant increase in 
muscle glycogen seen at 30min and 1h, no changes in phosphorylation of GSK3β were 
observed at any timepoint measured (30min-2h) (Figure 3.3). This is somewhat 
surprising, since GSK3β contributes to the regulation of glycogen synthesis by 
phosphorylating and inhibiting glycogen synthase. However, transient changes in p-
GSK3β may have preceded the increase in glycogen content and been missed in our 
studies.  
 Following these early changes, the next event observed was an increase in AMPK 
Ser
485/491 
phosphorylation, which was increased by 250% after 1h of incubation in a high 
glucose medium (Figure 3.1C). Prior studies in other tissues suggest that phosphorylation 
at this site in response to other stimuli occurs very quickly (within 5-10min) and plays an 
important role in inhibiting AMPK [54,56,59,239].  
 In the muscles incubated with high glucose, changes in NAMPT and redox state, 
as well as decreased SIRT1 expression (Figure 3.2), all of which also have been linked to 
diminished AMPK activity [234], occurred at various times after the decreases in Thr
172
 
and SAMS peptide phosphorylation (both of which were observed at 30min). The 
reduction in SIRT1 abundance first became evident at 2h, well after the initial decrease in 
AMPK activity. Previous studies have revealed an interaction between SIRT1 and the 
AMPK kinase LKB1. For example, Lan et al.[243] demonstrated that overexpression of 
SIRT1 led to increased AMPK activity by causing translocation of LKB1 from the 
nucleus to the cytoplasm, where most of the cellular AMPK is located. Whether a 
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decrease in SIRT1 leads to opposite changes and contributes to a reduction in AMPK 
activity is not known.  
 Another finding in the incubated EDL and muscles of glucose infused rats was an 
increase in PP2A activity (Figure 3.4). The dephosphorylation of AMPK at Thr
172
 has 
been associated with the actions of various Ser/Thr protein phosphatases [246]. Wu and 
coworkers [240] found that a decrease in AMPK activity observed in bovine aortic 
endothelial cells after incubation with palmitate for 40h is associated with an increase in 
PP2A activation. Surprisingly, the increase in PP2A activity in the present study occurred 
much later (2h) than the initial decreases in AMPK Thr
172
 phosphorylation (30min). 
Hyperactivity of PP2A has been shown in muscle and other tissues in models of 
glucolipotoxicity and diabetes [256]. Since this is the last factor to change of those that 
were examined, one could speculate that the increase in PP2A activity produces a less 
reversible inhibition of AMPK by maintaining its dephosphorylation on Thr
172
, and 
possibly other sites.  
 In vivo, the infusion of glucose concurrently decreased AMPK activity (SAMS 
peptide assay and p-AMPK Thr
172
) and increased AMPK Ser
485/491
 phosphorylation in the 
red gastrocnemius (Figure 3.5). The co-occurrence of these changes in vivo differed from 
the delay in phosphorylation at Ser
485/491
 observed in the EDL incubated with high 
glucose. Although the precise explanation for this difference remains to be determined, 
one obvious factor could be the presence of insulin in vivo. As already noted, in heart, 
insulin has been shown both to increase AMPK Ser
485/491 
phosphorylation and decrease 
the phosphorylation of αAMPK at Thr172 and AMPK activity within 5-10min [54,239]. 
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Of further note, we observed changes in SIRT1 and related parameters at the same time 
as the changes in Thr
172 
and Ser
485/491 
phosphorylation in the muscle of glucose-infused 
rats. However, the increase in PP2A activity occurred much later, as it did in the EDL 
incubated in a high-glucose medium (without insulin). The presence of insulin and other 
circulating factors, as well as differences in animal age and weight could be responsible 
for the differences in the timing and sequence of changes between the two models; 
however, this remains to be determined.  
 In summary, we have demonstrated that incubation of EDL with high glucose 
resulted in diminished AMPK Thr
172
 phosphorylation and activity that continued to 
decrease over time. An in vivo glucose infusion also caused a reduction in AMPK 
activation along with changes in other putative regulators of the enzyme. In both models, 
concurrent or sequential changes in αAMPK Ser485/491 phosphorylation (increased), 
SIRT1 protein level (decreased), and PP2A activity (increased) were observed. Though 
all of these factors may diminish AMPK activity, glycogen content was the only 
regulatory factor found to be changed at 30 min in the incubated EDL (See Figure 3.7 for 
summary of observed changes over time). These data suggest that the initial inhibition of 
AMPK in response to high glucose or leucine may be due to sensing an increase in 
cellular energy state in the form of glycogen, though further studies are required to 
confirm this hypothesis. The physiological and/or pathophysiological significance of the 
later occurring changes that correlate with additional decreases in AMPK activity also 
requires further investigation. An interesting possibility is that they contribute to more 
long-lasting changes that could alter gene expression or mitochondrial function and are 
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less readily reversible. Future studies with an expanded time course in which these 
factors are individually inhibited or knocked down could address these questions. 
Subsequent studies in this thesis will focus on the phosphorylation of AMPK at Ser
485/491
 
to determine its role in inhibiting AMPK activity and possible regulatory factors.  
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Figure 3.7: Chapter 3 Summary 
Effects of high glucose on AMPK phosphorylation and activity as well as factors that 
may regulate it in EDL incubated in 25mM glucose (A) and in muscle of glucose infused 
rats (B) are shown in the illustration.  
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CHAPTER 4: Inhibition of AMPK via insulin-induced phosphorylation at Ser
485/491
  
Introduction 
As described in the previous chapter, we found that phosphorylation of AMPK at 
Ser
4855/491
 was increased in EDL incubated with 25 vs 5mM glucose for 1 or 2h and in 
muscle of rats infused with glucose for 5 or 8h. In the present studies, we sought to 
determine whether phosphorylation of this site contributes to the inhibition of AMPK 
activity, as has been reported in other tissues [54,59], and what upstream kinase(s) could 
be it. In the EDL, the increase in Ser
485/491
 phosphorylation was observed after the initial 
decrease in AMPK Thr
172
 phosphorylation and enzyme activity, whereas in the muscle of 
glucose-infused rats, the increase in serine phosphorylation occurred concurrently with 
the decreases in Thr
172 
phosphorylation and AMPK activity. One notable difference 
between the models is presence of insulin in the glucose-infusion model, which we 
hypothesized could be responsible for the difference in timing. It has previously been 
shown that insulin and insulin-like growth factor-1 (IGF-1), both of which are elevated in 
T2D, can stimulate phosphorylation of AMPK at Ser
485/491 
in heart [47, 64], white 
adipocytes [51], vascular smooth muscle [48] and tumor cells [53] through activation of 
Akt (See Figure 1.1). For these reasons, we sought to investigate whether insulin 
stimulates AMPK Ser
485/491 
phosphorylation and inhibits enzyme activity in muscle. The 
C2C12 mouse skeletal muscle cell line was used in these studies to evaluate signaling 
pathways. These cells differentiate into myotubes that express characteristic muscle 
proteins and can be stimulated to contract.  
  
75 
Results 
Insulin stimulated phosphorylation of AMPK Ser
485/491 
in C2C12 myotubes and rat EDL 
muscle 
 To determine whether insulin treatment stimulates phosphorylation of AMPK at 
Ser
485/491
 in muscle, C2C12 myotubes and rat EDL muscle were treated with insulin for 
10-15min. Insulin treatment (100nM) significantly increased p-AMPK Ser
485/491 
in 
C2C12 myotubes (Figure 4.1A, 4.1B) by >5-fold. Similarly, incubation of rat EDL 
muscle with insulin increased AMPK Ser
485/491 
phosphorylation within 10 minutes 
(Figure 4.1C, 4.1D). Although 100nM is supraphysiological, increases in serine 
phosphorylation were seen in the myotubes with doses in the picomolar range, and 
timecourse studies revealed that increases were seen as early as 10 minutes and lasted at 
least 3 hours (See Supplemental Figure 4.7 for dose response). 
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Figure 4.1: Insulin stimulates phosphorylation of AMPK Ser485/491 in C2C12 myotubes and incubated EDL 
muscle.  
C2C12 myotubes (A) were cultured in normal glucose (5.5 mM), serum starved 
overnight, and stimulated with insulin (100 nM) for 15 min. Rat EDL muscles were 
removed and equilibrated in Krebs–Henseleit buffer for 20min, then stimulated with 
insulin (10 mU/ml) for 10min (C). Western blot analyses were performed, and 
representative blots are shown. Blots were quantified by densitometry. Phosphorylation 
of AMPK was normalized to total AMPK, and normalized data are displayed for 
myotubes (B) and EDL (D). Results are means ± SE (n = 3–6 per treatment). All 
experiments were performed in triplicate. ∗p < 0.05 vs. control. [239] 
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Insulin reduced AMPK activity in C2C12 myotubes and rat EDL muscle 
 Our results also showed that insulin significantly diminished AMPK activity, as 
measured by the SAMS peptide assay, in C2C12 myotubes and incubated EDL muscles 
(Figure 4.3), despite no change in p-AMPK Thr
172
 (Figure 4.1C, 4.1D). Phosphorylation 
of ACC Ser
79
 was also unchanged in response to insulin treatment in the myotubes; 
however, insulin diminished p-ACC Ser
79
 in the incubated EDL muscle (Figure 4.1C). 
The reason for this discrepancy is not yet known. 
Inhibition of Akt attenuated insulin-induced p-AMPK Ser
485/491
 and partially prevented 
the reduction in AMPK activity 
 The enzyme Akt has been shown by others to be responsible for the 
phosphorylation of Ser
485/491
 in other tissues. Since Akt plays an important role in the 
insulin signaling pathway, we used an inhibitor of Akt, Akt inhibitor VIII, to test the role 
of Akt on insulin’s stimulation of p-AMPK Ser485/491 in myotubes. Pretreatment of 
myotubes for 2h with this inhibitor attenuated the insulin-stimulated increase in 
phosphorylation of AMPK at Ser
485/491
 (Figure 4.2A, 4.2B). No changes were observed in 
p-AMPK Thr
172
 (Figure 4.2A, 4.2B). We measured AMPK α1 and α2 activity (α2 is the 
predominant isoform in skeletal muscle) and found that Akt inhibition significantly 
attenuated insulin’s effect on kinase activity in both C2C12 myotubes and EDL (Figure 
4.3A and 4.3C, respectively). Notably, a significant inverse correlation was observed 
between insulin-induced phosphorylation of Ser
485/491
 of AMPK and inhibition of AMPK 
activity (Figure 4.3B), despite no changes in p-AMPK Thr
172
, which is often assumed to 
be a surrogate readout for AMPK enzyme activity. 
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Wortmannin prevented insulin-induced phosphorylation of AMPK Ser
485/491
 
 To further confirm that Akt is responsible for insulin-stimulated phosphorylation 
of AMPK Ser
485/491
, we used the PI3K inhibitor wortmannin. Since PI3K is upstream of 
Akt in the insulin-signaling pathway, wortmannin should prevent Akt activation in 
response to insulin. We found that wortmannin had the same effect as Akt inhibitor VIII 
in C2C12 cells. Specifically, pre-treatment with wortmannin (1h) prevented the insulin-
induced increase in p-AMPK Ser
485/491
, with no effect on p-AMPK Thr
172
 (Figure. 4.2C, 
4.2D).  
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Figure 4.2: Inhibition of Akt attenuates insulin stimulated phosphorylation of AMPK Ser485/491.  
C2C12 cells were treated with or without Akt inhibitor VIII (250 μM) for 2 h, then 
stimulated with insulin (100 nM) for 15 min. Cells were lysed and subjected to western 
blot analysis. Representative western blots are shown (A). Quantification of western blots 
was performed using densitometry, and AMPK phosphorylation was normalized to total 
AMPK (B). In Figure C, C2C12 cells were pre-treated with the PI3-kinase inhibitor 
wortmannin (10 nM) for 1 h, then stimulated with insulin (100 nM) for 15 min. Cells 
were processed and protein expression and phosphorylation were quantified as described 
in (A) and (B) and quantifications are shown in (D). Results are means ± SE (n = 3–6 per 
treatment). All experiments were performed in triplicate. ∗p < 0.05 indicates a significant 
effect of insulin vs. control, 
†
p < 0.05 vs. insulin treatment alone. [239] 
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Figure 4.3: Insulin-induced inhibition of AMPK activity is partially prevented by Akt inhibition.  
AMPK α1 and α2 activities were assessed using the SAMS peptide assay, as described in 
the materials and methods section. C2C12 (A) and EDL (C) AMPK activity data are 
presented. Correlations between Ser
485/491
 AMPK phosphorylation data from western blot 
analysis (Fig. 4.1) and AMPK activity are shown (B). [239]  
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IGF-1 mimicked the effect of insulin on p-AMPK Ser
485/491
and was attenuated by Akt 
inhibition 
 Insulin-like growth factor 1 (IGF-1) is an anabolic factor that, like insulin, signals 
through the PI3K-Akt pathway. It was recently published that IGF-1 dose-dependently 
stimulates phosphorylation of AMPK at Ser
485
 on the α1 subunit in vascular smooth 
muscle cells (VSMCs) [48], and the authors determined that Akt was the upstream kinase 
responsible for this serine phosphorylation. Additionally, since IGF-1 is upregulated in 
T2D, we examined whether IGF-1 could produce the same effect as insulin in C2C12 
cells. We found that IGF-1 treatment does increase the phosphorylation of AMPK 
Ser
485/491
 in a dose-dependent manner. Furthermore, we found that pre-treatment with Akt 
inhibitor VIII prevented IGF-1 stimulation of this phosphorylation (Figure 4.4A, 4.4B), 
just as it did with insulin.  
  
82 
 
Figure 4.4: IGF-1 phosphorylation of AMPK Ser485/491 is prevented by Akt inhibition.  
C2C12 cells were serum starved overnight and treated with or without Akt inhibitor VIII 
(Akti; 250 μM) for 2 h, then stimulated with IGF-1 (20 ng/ml) for 15 min followed by 
whole cell lysis and analysis by western blot. Representative western blots are shown 
(A). Densitometric analysis of western blots was used to quantify protein phosphorylation 
and expression. Phosphorylation of proteins of interest were normalized to the 
corresponding total protein, and results are presented as fold-change compared to control 
(B). Results are means ± SE (n = 3–6 per treatment). All experiments were performed in 
triplicate. ∗p < 0.05 indicates a significant effect of IGF-1, 
†
p < 0.05 for the effect of Akti 
VIII. [239]  
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Inhibition of mTOR by rapamycin did not affect insulin-stimulated p-AMPK Ser
485/491
 
 As previously noted, Dagon et al. recently showed that leptin can stimulate 
phosphorylation of α2AMPK Ser491 in the hypothalamus, and that this is mediated by the 
mTOR/p70S6Kinase (p70S6K) pathway [52]. Since insulin treatment is also known to 
activate p70S6K activity in myotubes [65, 66], we sought to determine whether this 
pathway might be involved in insulin-sitmulation of p-AMPK Ser
485/491
. To examine this 
question, myotubes were pretreated with the mTOR inhibitor rapamycin for 2 h prior to 
insulin-stimulation. As expected, insulin treatment increased the phosphorylation of 
mTOR Ser
2448
 and p70S6K Thr
398
, both of which were prevented by rapamycin (50nM). 
Interestingly, rapamycin had no effect on p-AMPK Ser
485/491
 stimulation caused by 
insulin (Figure 4.5) or IGF-1. These results suggest that the mTOR/p70S6K pathway is 
not involved in insulin- or IGF-1-induced phosphorylation of AMPK Ser
485/491
 in C2C12 
myotubes.  
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Figure 4.5: Insulin-stimulation of p-AMPK Ser485/491 is not affected by the mTOR inhibitor rapamycin.  
C2C12 cells  were treated with or without rapamycin (50 nM) for 2 h, then stimulated 
with insulin for 15 min. Cell lysates were run on western blots and protein expression and 
phosphorylation were quantified using densitometry. Representative western blots are 
shown (A). Densitometry results are presented in graphs (B). Results are means ± SE 
(n = 3–6 per treatment). All experiments were performed in triplicate. *p < 0.05 indicates 
a significant effect of insulin, 
†
p < 0.05 for the effect of rapamycin treatment. [239] 
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Discussion 
 The multitude of functions attributed to AMPK activation highlights the 
importance of understanding how its activity is regulated at a molecular level. Although 
the enzyme has many post-translational modifications, phosphorylation of αThr172 has 
received the most attention, by far. Phosphorylation of this site is required to achieve 
maximal activity [40,41] and often corresponds with enzyme activity. Thus, it is often 
used as a readout of AMPK enzyme activity irrespective of kinase activity toward its 
downstream substrate, ACC, or its target sequence on ACC, known as SAMS (substrate 
for AMPK) peptide. In these studies, we measured the propensity of AMPK’s catalytic α-
subunit to phosphorylate SAMS peptide in vitro in settings where phosphorylation of 
AMPK at Ser
485/491
 was increased. We found decreases in AMPK activity with no 
changes in phosphorylation at Thr
172
. These results, along with those of others [59], 
contribute to a growing body of literature showing discordance between phosphorylation 
at Thr
172
 and activity towards SAMS peptide, but an inverse correlation between Ser
485/491
 
phosphorylation and activity towards SAMS peptide. 
 In these studies, we show, for the first time, that insulin and IGF-1 caused 
phosphorylation of AMPK at Ser
485/491
 in skeletal muscle. This has previously been 
shown in other tissues, such as heart, where Horman et al. [54] demonstrated in rat heart 
that at a normal glucose concentration, insulin increases αAMPK Ser485/491 
phosphorylation within 5 min, an effect mediated by Akt activation. In another series of 
investigations, Dagon et al [59] demonstrated that phosphorylation of α2 AMPK at Ser491 
in response to leptin inhibits its activity in the hypothalamus. They demonstrated that this 
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increase in AMPK Ser
491 
phosphorylation is mediated by mTOR/p70S6 kinase and can be 
inhibited by the mTOR inhibitor rapamycin. Since the mTOR/p70S6K is also activated 
by insulin, we used rapamycin to determine whether p70S6K is involved in Ser
485/491 
phosphorylation in muscle cells. Rapamycin had no effect on insulin-induced serine 
phosphorylation of AMPK, suggesting that p70S6K is not responsible for the inhibition 
of AMPK in this setting. Inhibition of Akt, however, did prevent insulin- and IGF-1-
stimulated phosphorylation of AMPK at Ser
485/491
. Both the Akt inhibitor Akt VIII and 
the PI3K inhibitor Wortmannin prevented insulin-stimulated serine phosphorylation of 
AMPK, suggesting that Akt is the kinase responsible for phosphorylating and inhibiting 
AMPK in response to insulin (See Figure 4.6). 
The physiological significance of insulin mediated inhibition of AMPK through 
Ser
485/491 
phosphorylation remains to be determined. Since AMPK stimulates catabolic 
processes aimed to restore normal ATP levels when cellular energy levels are low, 
whereas Akt is activated when cellular energy is high, the Akt mediated inhibition of 
AMPK likely represents a switch from a catabolic to anabolic state. In a healthy 
individual, this would allow for synthesis of proteins and glycogen in order to maintain 
muscle health and store energy for when it is needed. However, in states of chronic 
nutrient excess, sustained hyperinsulinemia and elevated IGF-1 levels, both of which are 
present in obesity, prediabetes, and T2D, could cause chronic inhibition of AMPK 
through this mechanism. As discussed in the introduction, this inhibition may contribute 
to the pathologies of insulin resistance by inhibiting glucose uptake and FA oxidation, 
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while prevention of AMPK through this mechanism could represent a novel prevention or 
treatment strategy for T2D.  
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Figure 4.6: Summary of Chapter 4 results. 
We found that both insulin and IGF-1 stimulate phosphorylation of AMPK at Ser
485/491
 
and diminish its activity in skeletal muscle. These events can be prevented by inhibition 
of PI3K and Akt, but not mTOR/p70S6K, suggesting that Akt is the kinase responsible 
for this inhibitory phosphorylation. 
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Supplemental Figure 4.7: Insulin dose-dependently stimulates phosphorylation of AMPK Ser485/491 in C2C12 
myotubes. 
C2C12 myotubes cultured in 5.5mM glucose were serum starved overnight, then treated 
with 10pM-100nM insulin for 15 min. Cells were lysed an analysed by western blot for 
phosphorylation of AMPK Ser
485/491
. 
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CHAPTER 5: Inhibition of AMPK via PKD1-mediated phosphorylation at Ser
485/491
 
Introduction 
 The studies presented in the previous chapter showed that insulin-mediated 
activation of Akt caused phosphorylation of AMPK at Ser
485/491
, resulting in inhibition of 
enzyme activity. In studies described in chapter 3, we showed that incubation of rat EDL 
muscle with elevated glucose levels (25mM) for 1 or 2h decreased AMPK activity 
(Figure 3.1A, 3.1D) and increased phosphorylation of AMPK at Ser
485/491
 (Figure 3.1C) 
in the absence of insulin, suggesting that a different mechanism may be involved. 
Similarly, it was reported that when MIN6 pancreatic beta cells were switched from low 
glucose (3mM) culture medium to high glucose (25mM) without insulin, for either 1h or 
overnight, phosphorylation of α1AMPK at Ser485 was increased [61]. This serine 
phosphorylation was inversely correlated to phosphorylation of AMPK Thr
172
.  
 Several upstream kinases have been identified that phosphorylate AMPK at 
Ser
485/491
 and inhibit its activity in various tissues. As previously mentioned, in heart, 
skeletal muscle, and liver, insulin and IGF-1 stimulate AMPK phosphorylation at this site 
by activating Akt [54,55,58,239]. Also, in the hypothalamus, Dagon et al. [59] showed 
that p70S6K phosphorylates α2AMPK Ser491 to inhibit AMPK activity and decrease food 
intake. Others have shown that in murine macrophage-like RAW 264.7 cells, IKKβ 
phosphorylates AMPK at Ser
485
 in response to LPS treatment [257], while ERK1/2 can 
inhibit AMPK by this mechanism in mature dendritic cells in response to CCR7 signaling 
[258]. Finally, protein kinase A (PKA) has been reported to phosphorylate this site in 
INS-1 cells in response to forskolin or GIP stimulation [56] and in human diploid 
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fibroblasts in response to lysophosphatidic acid [259]. Inhibition of AMPK through this 
mechanism by multiple kinases suggests a biological need to maintain tight control over 
AMPK enzyme activity. Whether other kinases can also phosphorylate AMPK at 
Ser
485/491 
to modulate its activity and their biological functions remain to be determined.  
 Protein Kinase C (PKC) is a family of serine/threonine kinases that can be 
activated by diacylglycerol (DAG), a phospholipid, and Ca
2+
 (depending on the isoform). 
Several of the 10 known PKC isoforms have long been implicated in the development of 
insulin resistance, but beyond inhibitory serine phosphorylation of IRS-1 [209], the 
mechanisms by which they do so have not been fully clarified. Protein Kinase D1 
(PKD1) (the mouse ortholog of human PKCμ) is a related kinase that can be activated 
either directly by DAG or due to phosphorylation by novel PKC isoforms [218]. When 
activated, PKD1 undergoes transphosphorylation by novel PKCs at Ser
744/748
 of its 
activation loop and autophosphorylation at Ser
916
 at its C terminus. This more recently 
discovered enzyme was initially classified as an atypical PKC isoform, but was later 
determined to be more similar structurally to the calcium/calmodulin-dependent protein 
kinase (CaMK) group of serine/threonine kinases with unique substrate specificity 
[217,218]. Pathological overactivation of PKD1 has been linked to invasiveness of 
certain cancers [260] and cardiac hypertrophy [222,224], the latter of which is often 
present in patients with T2D. Interestingly, both PKD1 and AMPK can act as class IIa 
histone deacetylase (HDAC) kinases [261]. Phosphorylation of HDAC5 by these kinases 
allows the transcription factor myocyte enhancer factor 2 (MEF2) to dissociate and 
upregulate many muscle-specific and metabolic genes. This pathway is responsible for 
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adaptations to acute exercise and may mediate the hypertrophic response to PKD1 
overactivation. Recently, McGee and colleagues [228] reported that expression of a 
dominant negative AMPK in the muscle of mice resulted in a compensatory increase in 
PKD1 activation during exercise. Whether alterations in PKD1 expression or activity 
affect AMPK activation is not yet known. What is known is that the DAG mimetic 
phorbol 12-myristate 13-acetate (PMA), which activates PKC and PKD, as well as many 
other signaling molecules, decreases AMPK activity in cardiac myocytes [216], although 
the mechanism by which it does so is unknown. 
 In the present studies, we sought to determine whether PKC or PKD may be 
involved in inhibition of AMPK through phosphorylation at Ser
485/491
 in skeletal muscle 
cells. We used the phorbol ester PMA to determine the effects of broad PKC/PKD 
activation on AMPK phosphorylation and activity. Through the use of non-specific and 
specific PKC and PKD inhibitors, we show for the first time that PKD1 phosphorylates 
AMPK at Ser
485/491
, thus diminishing AMPK activity. 
 
Results 
The PKC activator PMA dose- and time-dependently stimulated AMPK Ser
485/491 
phosphorylation in C2C12 myotubes 
 Treatment with the PKC activator phorbol 12-myristate 13-acetate (PMA) has 
previously been shown to decrease AMPK activity in cardiac myocytes, as measured by 
the SAMS peptide assay [216]. We sought to determine whether PMA had the same 
effect in C2C12 myotubes, and if so, whether it is mediated by an inhibitory 
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phosphorylation on AMPK’s α1/α2 subunit at Ser485/491. All doses of PMA (10-100nM) 
significantly increased serine phosphorylation of AMPK (Figure 1A, 1B), as did PMA 
treatments of 30min-3h (50nM) (Figure 5.1C, 5.1D). Increases in overall PKC activity, as 
measured by serine phosphorylation of PKC substrates (data not shown), mirrored the 
increases in phosphorylation of AMPK Ser
485/491 
(Figure 5.1D). Phosphorylation of PKD 
at Ser
916  
and Ser
744/748
 of its activation loop were also significantly increased by PMA at 
doses of 25nM or higher and treatments of 30min-3h (Figure 5.1A-D). Since 
phosphorylation of these two sites changed similarly in response to all treatments, only 
Ser
916
 phosphorylation will be shown in subsequent experiments. Notably, no significant 
changes in phosphorylation of AMPK Thr
172
 (Figure 5.1A, 5.1C) or its downstream 
substrate ACC Ser
79
 were observed. Phosphorylation of conventional PKC isoforms, as 
measured by p-PKC (pan) (βII Ser660), was increased in a dose-response manner; 
however, activation of the atypical PKCι was not increased by PMA treatment 
(Supplemental Figure 5.12). 
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Figure 5.1: PMA treatment time- and dose-dependently stimulates phosphorylation of AMPK at Ser485/491 in 
C2C12 myotubes.  
Myotubes were treated with 10-100nM PMA for 30min (A, B) or 50nM PMA for 5-
180min (C, D). Cells were lysed and protein expression and phosphorylation were 
analyzed by western blot. Representative western blots (A, C) and their densitometric 
analyses (B, D) are shown. Results are means ± SE (n = 3–6 per treatment). All 
experiments were performed in triplicate. *P<0.05 compared to control. 
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The non-selective PKC inhibitor Gӧ6983 prevented PMA-induced phosphorylation of 
AMPK Ser
485/491 
 To determine whether the increase in phosphorylation of AMPK at Ser
485/491
 was 
attributable to PKC activation, we used the non-selective PKC inhibitor Gӧ6983. 
Treatment of C2C12 myotubes with Gӧ6983 (5µM) for 1h prior to PMA treatment 
(50nM, 30min) significantly attenuated phosphorylation of AMPK at Ser
485/491 
(Figure 
5.2A, 5.2B). Phosphorylation of AMPK Thr
172
 (Figure 5.2A) was not affected by PMA 
treatment, but it was increased by the inhibitor. We found that overall PKC activity was 
decreased by the inhibitor (Figure 5.2A), as was phosphorylation of conventional PKC 
isoforms, as evaluated by p-PKC (pan) (βII Ser660), and p-PKD Ser916 (Figure 5.2A, 
5.2B), but not p-PKC δ/θ (Ser643/676). 
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Figure 5.2: PKC inhibition prevents PMA-induced phosphorylation of AMPK Ser485/491 in C2C12 myotubes.  
Myotubes were treated with the non-specific PKC inhibitor Gӧ6983 (5M) for 1h prior to 
PMA treatment (50nM, 30min). Cells were lysed and protein expression and 
phosphorylation were analyzed by western blot. Representative western blots (A) and 
their densitometric analyses (B) are shown. Results are means ± SE (n = 3–6 per 
treatment). All experiments were performed in triplicate. *P<0.05 compared to control, † 
p<0.05 compared to PMA treatment. 
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The selective PKD-1 inhibitor CRT0066101 prevented PMA-induced phosphorylation of 
AMPK Ser
485/491 
 Since phosphorylation of the activation loop of PKD at Ser
744/748 
and
 
at Ser
916
 
(Figures 5.1, 5.2, Supplemental Figure 5.10) corresponded with changes in 
phosphorylation of AMPK at Ser
485/491
, we investigated whether specific inhibition of 
PKD could attenuate PMA-induced serine phosphorylation of AMPK. We found that pre-
treatment for 1h with the specific PKD inhibitor CRT0066101 (10µM) prevented 
phosphorylation of AMPK Ser
485/491
 in C2C12 cells (Figure 5.3A, 5.3B, see 
Supplemental Figure 5.11 for dose response). Phosphorylation of AMPK at Thr
172
 was 
unchanged by treatment with this inhibitor (Figure 5.3A). As expected, PKD Ser
916
 
phosphorylation was ablated by CRT0066101 treatment, and probing with a phospho-
(Ser/Thr) PKD substrate antibody revealed an overall increase in number of bands and 
band intensity with PMA treatment, which was prevented by pretreatment with 
CRT0066101 (Figure 5.3A). Bands detected by this antibody at 110kDa and 62kDa may 
represent PKD (which is autophosphorylated at Ser
916
) and AMPK, respectively. 
  
98 
 
Figure 5.3: PKD inhibition prevents PMA-induced phosphorylation of AMPK Ser485/491 in C2C12 myotubes.  
Myotubes were treated with the specific PKD inhibitor CRT0066101 (10M) for 1h prior 
to PMA treatment (50nM, 30min). Cells were lysed and protein expression and 
phosphorylation were analyzed by western blot. Representative western blots (A) and 
their densitometric analyses (B) are shown. Results are means ± SE (n = 3–6 per 
treatment). All experiments were performed in triplicate. *P<0.05 compared to control, † 
p<0.05 compared to PMA treatment. 
 
  
99 
PMA treatment inhibited AMPK activity, which was attenuated by pretreatment with 
Gӧ6983 or CRT0066101 
 Recent studies have shown that phosphorylation of AMPK Ser
485/491
 can inhibit its 
activity, even in the absence of diminished Thr
172 
phosphorylation, which is often used as 
a surrogate readout for enzyme activity [59,239]. We sought to determine whether the 
changes in phosphorylation of AMPK Ser
485/491
 caused by PMA and the PKC inhibitors 
Gӧ6983 and CRT0066101 corresponded to changes in AMPK activity. Using the SAMS 
peptide assay described in the methods section, we found that PMA treatment 
significantly decreased α2 AMPK activity in C2C12 myotubes (Figure 5.4A, 5.5A). 
Furthermore, we found that pretreatment with the non-selective PKC inhibitor Gӧ6983 
significantly attenuated the reduction in enzyme activity (Figure 5.4A), while the specific 
PKD inhibitor CRT0066101 completely prevented the PMA-induced decrease in AMPK 
activity (Figure 5.5A). Despite the lack of changes in phosphorylation of AMPK Thr
172 
or 
ACC Ser
79
, we found a significant inverse correlation between AMPK activity and 
phosphorylation at Ser
485/491
 (Figure 5.4B, 5.5B). 
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Figure 5.4: PMA treatment diminishes AMPK activity in C2C12 myotubes, while PKC inhibition prevents this 
decrease.  
C2C12 myotubes were treated with the non-specific PKC inhibitor Gӧ6983 (5M) for 1h 
prior to PMA treatment (50nM, 30min). AMPK2 activity was measured by the SAMS 
peptide assay (A). (B) shows the correlation between AMPK2 activity and Ser485/491 
phosphorylation. Results are means ± SE (n = 3–6 per treatment). *P<0.05 compared to 
control, † p<0.05 compared to PMA treatment. 
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Figure 5.5: PMA treatment diminishes AMPK activity in C2C12 myotubes, while PKD inhibition prevent this 
decrease.  
C2C12 myotubes were treated with the specific PKD inhibitor CRT0066101 (10M) for 
1h prior to PMA treatment (50nM, 30min). AMPK2 activity was measured by the 
SAMS peptide assay (A). (B) shows the correlation between AMPK2 activity and 
Ser
485/491
 phosphorylation. Results are means ± SE (n = 3–6 per treatment). *P<0.05 
compared to control, † p<0.05 compared to PMA treatment. 
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Inhibition of Akt, P70S6K, or ERK did not prevent PMA-induced phosphorylation of 
AMPK Ser
485/491 
 As previously mentioned, the kinases Akt, P70S6K, and ERK1/2 have been 
shown to phosphorylate AMPK at Ser
485/491
 in response to various stimuli in other cell 
types. To rule out involvement of these kinases in PMA-induced phosphorylation of 
AMPK Ser
485/491
, we used inhibitors of each of these kinases. Pretreatment of C2C12 
myotubes with the PI3K/Akt inhibitor wortmannin (100nM) did not affect PMA-
stimulated serine phosphorylation of AMPK (Figure 5.6A). As expected, PMA treatment 
did not increase Akt phosphorylation, but p-Akt Ser
473
 phosphorylation was diminished 
by wortmannin treatment. Next, we used the mTOR inhibitor rapamycin to test whether 
P70S6K was involved. Although P70S6K Thr
389
 phoshphorylation was increased by 
PMA treatment, rapamycin (100nM) treatment did not did not affect PMA-induced 
phosphorylation of AMPK Ser
485/491
 (Figure 5.6B). Similarly, pretreatment with the ERK 
inhibitor U0126 (5µM) had no effect on AMPK serine phosphorylation (Figure 5.6C), 
despite inhibiting ERK phosphorylation, which can occur downstream of PKD. 
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Figure 5.6: Inhibition of Akt, S6K, or ERK does not prevent PMA-induced phosphorylation of AMPK Ser485/491.  
Myotubes were treated with the PI3K/Akt inhibitor wortmannin (100nM) (A), the 
mTOR/P70S6K inhibitor rapamycin (100nM) (B), or the ERK inhibitor U0126 (5M) 
(C) for 2h prior to PMA treatment (50nM, 30min). Cells were lysed and protein 
expression and phosphorylation were analyzed by western blot. Representative western 
blots and their densitometric analyses are shown. Results are means ± SE (n = 3–6 per 
treatment). All experiments were performed in triplicate. *P<0.05 compared to control, † 
p<0.05 compared to PMA treatment. 
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PMA treatment inhibited insulin signaling through Akt, which was attenuated by 
pretreatment with Gӧ6983 or CRT0066101 
 In order to test whether the PMA-induced changes we were seeing are associated 
with impaired insulin signaling, we measured insulin-stimulated Akt phosphorylation. 
PMA treatment (50nM) for 30min diminished insulin-stimulated Akt Ser
473
 
phosphorylation (Figure 5.7A, 5.7B). Pretreatment with Gӧ6983 or CRT0066101 
restored insulin signaling through Akt. Since both insulin and PMA independently 
stimulate AMPK Ser
485/491
 phosphorylation through Akt and PKD, respectively, all 
combinations of insulin and PMA with and without inhibitors significantly increased 
serine phosphorylation of AMPK (Figure 5.7A, 5.7B). PMA treatment with insulin did 
not further increase Ser
485/491
 phosphorylation beyond that of insulin alone, suggesting 
that the dose (100nM) and time (15min) of insulin treatment stimulates maximal serine 
phosphorylation of AMPK in C2C12 cells. 
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Figure 5.7: PMA treatment impairs insulin signaling through Akt, which is prevented by PKC and PKD 
inhibition.  
C2C12 myotubes were treated with or without Gӧ6983 (5µM) or CRT0066101 (10 µM) 
for 1h prior to PMA treatment (30min), followed by insulin stimulation (100nM, 15min). 
Cells were lysed and Akt, AMPK, and PKD phosphorylation were analyzed by western 
blot. Representative blots (A) and quantifications (B) are shown. *P<0.05 compared to 
control, † p<0.05 compared to insulin treatment 
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Recombinant PKD phosphorylated AMPK2 at Ser491 in cell-free conditions 
 To determine whether PKD phosphorylates AMPK directly or if a molecule 
downstream of PKD is required, we tested whether recombinant PKD phosphorylates 
AMPK in a cell-free system. Compared to AMPKα2 alone, co-incubation of recombinant 
PKD with AMPKα2 caused phosporylation of AMPKα2 at Ser491 (Figure 5.8A). 
Incubation of Akt, used as a positive control, with AMPK also caused an obvious 
increase in Ser
491
 phosphorylation. This data suggests that PKD phosphorylates AMPK 
directly. To evaluate whether AMPKα2 Ser491 is a good substrate for PKD, we lined up 
the PKD substrate consensus sequence with the sequence of residues preceding Ser
491
 on 
AMPKα2. Although AMPKα2 has a proline rather than PKD’s preferred leucine at the -5 
position, the arginine at the -3 position does line up (Figure 5.8B). This is similar to Akt, 
which prefers arginine at both the -5 and -3 positions. 
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Figure 5.8: Recombinant PKD1 phosphorylates AMPK at Ser485/491 in a cell-free assay.  
Recombinant AMPK2/β1/ϒ1 was incubated with recombinant PKD1 or recombinant 
Akt as described in the methods section. Phosphorylation of AMPK at Ser
491 
was 
evaluated by western blot (A). The consensus substrate motifs of PKD and Akt were 
lined up with residues 486-491 of AMPK2 (B). n=3 per group. All experiments were 
performed in triplicate. 
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Discussion 
 A better understanding of how AMPK is regulated at a molecular level is 
important for improving drug-targeting strategies for T2D. Phosphorylation of AMPK at 
Thr
172
 of the activation loop is essential for the activation of AMPK and is often used as 
readout for activity. However, our data adds to a growing number of studies showing that 
phosphorylation of AMPK at Ser
485/491
 can inhibit AMPK activity, even in the absence of 
changes in p-AMPK Thr
172
. Although p-AMPK Thr
172
 is often used as a measure of 
AMPK activity, these data suggest that phosphorylation of AMPK at Ser
485/491 
can inhibit 
AMPK activity independent of changes in p-AMPK Thr
172
 and that inhibition of p-
AMPK Thr
172
 is not required for Ser
485/491 
phosphorylation to induce inhibition of AMPK 
activity. We show, for the first time, that PKD1 activation can stimulate phosphorylation 
of AMPK Ser
485/491
 in skeletal muscle cells, resulting in impaired insulin signaling. Not 
only does this work identify a novel kinase that can inhibit AMPK by serine 
phosphorylation at this site, but it also presents a possible mechanism by which AMPK 
may be inhibited by excess nutrients since DAG (which activates PKD) is known to be 
activated by high glucose and lipids. 
 In 2012, Tsuchiya et al. [216] demonstrated that 60min PMA treatment (1μM) 
inhibits AMPK activity by approximately 33% in cardiac myocytes, as measured by the 
SAMS peptide assay. They found that this inhibition could be prevented by the non-
specific PKC inhibitor bisindoylmaleimide I (BIM I) or the ERK inhibitor U0126, which 
led them to conclude that PMA inhibits AMPK by a mechanism involving the PKC and 
ERK pathways. There was no apparent change in energy state (AMP/ATP ratio) 
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accompanying this decrease in AMPK activity. To our knowledge, this was the first 
report of PMA treatment causing inhibition of AMPK; however, AMPK phosphorylation 
at Thr
172
 or Ser
485/491
 was not measured. In concert with these results, we found that PMA 
treatment significantly diminished AMPK activity in C2C12 myotubes (Figure 3A, 3C). 
However, we found that a dose of only 50nM for 30min resulted in a 50-60% decrease in 
AMPK activity, nearly twice as much as was seen in the cardiac myocytes. This 
discrepancy could be due to differences in cell type or methodologies. 
 Several kinases have been reported to phosphorylate AMPK at Ser
485/491
.  We 
[239] and others [54] have shown that Akt phosphorylates and inhibits AMPK in muscle, 
liver, and heart in response to insulin. In the hypothalamus, the mTOR/p70S6 kinase 
pathway has been reported to cause this inhibitory event in response to leptin [59], and 
this signaling mechanism was shown to be essential for mediating the anorectic effects of 
leptin. In murine macrophage-like RAW 264.7 cells, Park and colleagues [257] showed 
that IKKβ phosphorylates AMPK at Ser485 in response to LPS treatment. ERK1/2 was 
recently shown to phosphorylate AMPK on this serine residue in mature dendritic cells 
[258]; this may be important mechanism by which CCR7 signaling promotes cell 
survival. Furthermore, protein kinase A (PKA) has been reported to act as an upstream 
kinase for AMPK Ser
485/491
 in INS-1 cells in response to forskolin or GIP stimulation [56] 
and in human diploid fibroblasts in response to lysophosphatidic acid [259]. In our 
studies, we ruled out Akt, S6K and ERK as upstream kinases responsible for AMPK 
Ser
485/491
 phosphorylation in response to PMA through the use of specific inhibitors of 
each enzyme (Figure 4). However, we found that pretreatment with the non-selective 
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PKC inhibitor Gö6983 significantly attenuated the decrease in AMPK activity, while the 
PKD inhibitor CRT0066101 completely prevented this inhibition (Figure 3A, 3C). 
Furthermore, we found a significant inverse correlation between AMPK activity and 
phosphorylation at Ser
485/491
 under these conditions, suggesting that PKD1 is responsible 
for the serine phosphorylation and inhibition of AMPK in this setting (Figure 3B, 3D). 
The fact that recombinant PKD1 phosphorylates AMPK2 at Ser491 in cell-free 
conditions supports our hypothesis that PKD1 is a direct upstream kinase of this site 
(Figure 5.7). 
 Many of the aforementioned kinases that can mediate AMPK inhibition through 
Ser
485/491
 phosphorylation are associated with anabolic or pro-hypertrophic signaling 
pathways (Akt, mTOR/P70S6K). This is not surprising, since AMPK is generally 
activated under low energy conditions that favor catabolic processes, and thus inhibited 
under conditions of energy overload that favor anabolic processes. Consistent with this, 
PKD has recently been identified as having pro-hypertrophic functions. For example, 
Harrison et al. [224] reported that transgenic mice expressing a cardiac-specific, 
constitutively active PKD mutant develop cardiac hypertrophy, followed by ventricular 
chamber dilation, wall thinning, and contractile dysfunction. They also showed that 
PKD1 expression and activity are significantly increased in the myocardium of 
spontaneously hypertensive heart failure rats, an effect which is further exaggerated by 
thoracic aortic banding. Furthermore, PKD1 activation was found to be elevated in hearts 
of humans with idiopathic dilated cardiomyopathy [222]. While these results suggest that 
PKD1 activation may be sufficient to induce pathological cardiac remodeling, the role of 
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PKD1 in skeletal muscle is less clear. McGee et al. [228] reported that loss of AMPK in 
muscle resulted in no change in HDAC5 phosphorylation during exercise, but a ~33% 
compensatory increase in PKD activation, suggesting potential redundancies in the 
functions of these two proteins in response to exercise. Although they did not investigate 
the effects of PKD loss or activation on AMPK activation, these data, together with our 
results, suggest that PKD and AMPK may negatively regulate each other in skeletal 
muscle.  
 Further evidence supporting potential redundancy of functions between AMPK 
and PKD1, at least in regards to HDAC5 phosphorylation in response to exercise, is the 
fact that mice overexpressing constitutively active PKD1 in skeletal muscle show 
resistance to fatigue in response to repetitive contraction and a shift to Type I and Type 
IIa muscle fibers [225], while expression of a dominant negative kinase dead PKD1 in 
skeletal muscle results in impaired running performance and prevents fiber type 
switching [262]. Similarly, it has long been known that AMPK mediates many 
adaptations of muscle to exercise [72], and loss of AMPK in muscle causes impairments 
in running capacity [73].  
 Our studies showed that PKD1 activation impaired insulin-signaling through Akt 
in C2C12 myotubes, which was prevented by PKD inhibition. Though we have not 
shown a direct role for AMPK inhibition being responsible this impairment, it is 
consistent with the fact that AMPK activation is known to promote insulin sensitivity 
[263]. This is the first report of PKD1 activation causing impaired insulin-signaling, and 
the mechanism by which it does so requires further investigation.  
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 We report a novel inhibitory relationship between PKD1 and AMPK in skeletal 
muscle cells whereby PKD inhibits AMPK directly by phosphorylating it at Ser
485/491
 of 
the 1/2 subunit. Since PKD1 may be activated directly by DAG (or the DAG mimetic 
PMA) or by novel PKC isoforms, we have not ruled out the possibility that novel PKC 
isoforms may also be involved upstream of PKD1 in these processes. Similarly, though 
we have shown that PKD1 activation is necessary for the inhibition of AMPK and the 
impairment of insulin signaling, further studies are required to determine whether 
Ser
485/491
 phosphorylation of AMPK is essential for mediating these impairments in 
insulin signaling. Our data suggest that PKD1 inhibition may be a novel strategy for 
preventing AMPK inhibition and impaired insulin sensitivity in muscle; however, based 
on the growing list of PKD1 functions in a variety of tissues being reported in the 
literature, this strategy would have to be approached with caution, and likely in a highly 
controlled, tissue specific manner.  
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Figure 5.9: Summary of Chapter 5 
In C2C12 myotubes, the DAG mimetic PMA stimulated phosphorylation of AMPK at 
Ser
485/491
 and reduced its activity, as measured by the SAMS peptide assay. This 
phosphorylation and inhibition were prevented by non-specific PKC inhibition and 
specific PKD inhibition, suggesting that PKD is responsible for phosphorylation and 
inhibition through Ser
485/491
 phosphorylation. 
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Supplemental Figure 5.10 
C2C12 myotubes were treated with 2-20µM Gӧ6983 for 1h prior to stimulation with 
50nM PMA (30min). Cells were lysed and analyzed by western blot. 
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Supplemental Figure 5.11 
C2C12 myotubes were treated with 0.1-50µM CRT0066101 for 1h prior to stimulation 
with 50nM PMA (30min). Cells were lysed and analyzed by western blot. *P<0.05 
compared to control, † p<0.05 compared to PMA treatment. 
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Supplemental Figure 5.12 
Myotubes were treated with 10-100nM PMA for 30min. Serine phosphorylation of PKC 
substrates, p-PKC (pan) (βII Ser660), and p-PKCι Thr555/p-PKCλ Thr563 were 
measured by western blot (A). Phosphorylation of PKCδ/θ Ser643/676, ACC Ser79, PKC 
(pan) (βII Ser660) were measured in myotubes treated with PMA (50nM, 30min) and the 
non-specific PKC inhibitor Gӧ6983 (5µM) or the specific PKD inhibitor CRT0066101, 
as indicated (B). Representative western blots are shown. Results are means ± SE (n = 3–
6 per treatment). All experiments were performed in triplicate.   
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CHAPTER 6: Physiological Regulation of AMPK Ser
485/491 
Introduction 
 The previous chapters have shown that both incubation of rat EDL muscle and 
infusion of glucose in vivo inhibited AMPK activity and caused inhibitory 
phosphorylation of AMPK at Ser
485/491
. We have also shown that phosphorylation of this 
site inversely correlates with AMPK activity and that Akt and PKD1 can act as upstream 
kinases of this inhibitory post-translational modification. Our next aim was to evaluate 
the regulation of AMPK Ser
485/491
 in the insulin-responsive tissues muscle and liver in 
response to physiological (fasting/refeeding) and pathological (obesity, T2D) changes in 
nutrition status. Phosphorylation of AMPK’s activation site Thr172 has been studied in 
detail in these settings; however, changes in inhibitory serine phosphorylation of AMPK 
and potential upstream mediators have not been studied. Since we have shown in the 
previous chapters that AMPK phosphorylation at Ser
485/491 
can inhibit AMPK activity 
independently of changes in p-AMPK Thr
172
 and that inhibition of p-AMPK Thr
172
 is not 
required for Ser
485/491
 phosphorylation to induce inhibition of AMPK activity, a better 
understanding of how Ser
485/491
 is regulated in response to a variety of stimuli could 
provide important insight into novel strategies and conditions for therapeutic AMPK 
activation. In the present studies, we investigated the activation of Akt and PKD1 in EDL 
incubated in high glucose and in muscle of glucose infused rats to determine whether 
these kinases may be playing a role in the phosphorylation of AMPK Ser
485/491
 in these 
settings. We also investigate the regulation of AMPK Ser
485/491
, Akt, and PKD1 in mice 
fasted overnight vs refed for 2h and in db/db mice, which are obese and insulin resistant.  
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Results 
DAG content and PKD1 activity, but not Akt, were increased in EDL incubated with 
25mM glucose 
In order to determine whether Akt or PKD1 were responsible for the 
phosphorylation of AMPK Ser
485/491
 observed in EDL incubated with high glucose for 1 
and 2h, we measured activation of these proteins by western blot. There were no 
significant changes in p-Akt Ser
473
 at any timepoint, but there was a trend toward 
increased Akt phosphorylation at 1h (p=0.12) (Figure 6.1A, 6.1C) As previously noted, 
no insulin was added to the incubation medium; however, the PI3K/Akt pathway can be 
activated by other signaling molecules, such as growth or survival factors. We also found 
that DAG content was significantly increased in the EDL following 1h incubation with 
25mM glucose (Figure 6.1B), suggesting activation of PKC/PKD signaling. Since the 
antibodies directed toward p-PKD Ser
916
 and Ser
744/748
 did not work in rat tissue, we 
measured phosphorylation of PKD serine substrates as a readout of PKD activity. 
Phosphorylation of PKD substrates showed a band at 110kDa, likely representing the 
autophosphorylation of PKD1 at Ser
916
, which was initially diminished at 0.5h in 25mM 
glucose, returned to basal levels at 1h, and was significantly increased following 2h in 
high glucose. 
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Figure 6.1: DAG content and PKD activation are increased in EDL incubated in high glucose 
EDL muscles were incubated in 25mM glucose (no insulin) for 0.5-2h. Muscles were 
analyzed by Western blot. Representative blots (A) were analyzed by densitometry (C). 
Intramuscular DAG content was also measured (B). *p<0.05 compared to 5.5mM glucose 
at each time point.   
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mTOR inhibition did not affect AMPK phosphorylation in response to high glucose, but 
PKD1 inhibition did prevent the phosphorylation of AMPK at Ser
485/491 
To confirm that the mTOR/P70S6K pathway was not responsible for the high 
glucose-induced phosphorylation of Ser
485/491
, we incubated EDL with the mTOR 
inhibitor rapamycin for 0.5h prior to incubation with 25mM glucose for 1h. Rapamycin 
prevented neither the decrease in AMPK Thr
172
 nor the increase in Ser
485/491
 
phosphorylation, though it did prevent the high glucose-induced increase in mTOR 
Ser
2448
 phosphorylation (Figure 6.2). However, when the EDL was pretreated with the 
PKD1 inhibitor CRT0066101 for 1h prior to incubation with high glucose for 2h, the 
phosphorylation of AMPK at Ser
485/491 
was prevented (Figure 6.3). 
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Figure 6.2: Inhibition of glucose-induced mTOR/p70S6K phosphorylation does not affect AMPK 
phosphorylation. 
EDL were preincubated in the presence of rapamycin (100μM) for 0.5h and then with 5.5 
or 25 mM glucose for 1hr. Muscle lysates were analyzed for P-AMPK Thr
172
 (A), P-
mTOR Ser
2448
 (B) and AMPK Ser
485/491
 (C) by western blot. Results show quantification 
of western blots by densitometry. Results are means ± SE (n = 5). *, p<0.05 compared to 
values for 5.5 mM glucose. 
 
Figure 6.3: PKD1 inhibition prevented high glucose-induced phosphorylation of AMPK at Ser485/491 in rat EDL. 
EDL muscle was incubated with 5.5mM glucose with or without 100uM CRT0066101 
prior to incubation with 5.5mM or 25mM glucose for 2h. Phosphorylation of AMPK 
Ser485/491 was measured by western blot. Representative blot (A) and densitometric 
analysis (B) are shown. Graph shows mean +/- SEM. *p<0.05 compared to incubation 
with 5.5mM glucose. N=4/group 
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Akt and PKD1 were increased by glucose infusion in vivo 
Next, we sought to determine whether Akt and PKD1 were activated in the 
muscle of glucose infused rats, where we had previously showed that AMPK Ser
485/491 
phosphorylation was increased at 5 and 8h (Figure 3.5). We found that Akt Ser
473
 
phosphorylation was significantly increased at all timepoints (Figure 6.4). Interestingly, 
we found that phosphorylation of PKD substrates at 110kDa, likely representing the 
autophosphorylation of PKD1 at Ser
916
 was initially unchanged, although there was a 
trend towards being decreased at 3h, and subsequently increased and was significantly 
elevated following 8h of glucose infusion.  
 
Figure 6.4: Akt and PKD1 activation are increased in muscle of glucose infused rats. 
Red gastrocnemius muscles from glucose-infused rats (3-8h) were analyzed by western 
blot for p-AMPK 
Ser485/491
, p-Akt Ser
473
, and p-(Ser) PKD substrate. Blots were analyzed 
by densitometry. Data are means ± SEM. n = 4–6 rats per group, P < 0.05 vs. 0h group. 
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Refeeding increased phosphorylation of AMPK at Ser
485/491
following an 18h fast in 
muscle and liver 
To determine the physiological regulation of AMPK Ser
485/491
 phosphorylation in 
response to feeding, we measured serine phosphorylation as well as Akt and PKD1 
activation in response to fasting and refeeding. C57Bl/6 mice were fasted for 18h and 
either sacrificed immediately or after a 2h refeeding period (Figure 6.5). Phosphorylation 
of AMPK at Ser
485/491
 was increased in both gastrocnemius muscle and liver of fed 
compared to fasted mice (Figure 6.6). As expected, p-Akt Ser
473
 was increased in both 
tissues following feeding, which would stimulate insulin secretion. Interestingly, p-PKD 
Ser
916 
was elevated in livers of fed mice compared to fasted, but there was no change in 
muscle of fasted vs. fed mice. 
 
 
Figure 6.5: Schematic showing protocol for fast/refeed study. 
C57BL/6 mice were fasted overnight for 18h. Half were sacrificed immediately, and half 
were sacrificed after re-feeding of a normal chow diet for 2h. 
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Figure 6.6: Refeeding (2h) increased phosphorylation of AMPK Ser485/491 in skeletal muscle, and of Ser485 and 
PKD Ser916 in the liver of mice following an 18h fast. 
Gastrocnemius muscle (A) and liver (B) from C57BL/6 mice fasted overnight (18h) or 
refed (2h) were analyzed by western blot. Representative blots are shown. Blots were 
quantified by densitometry.  
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Phosphorylation of AMPK Ser
485/491 
was unchanged in muscle but increased in liver of 
db/db mice compared to db/+ mice 
 Next, we sought to determine whether phosphorylation of AMPK Ser
485/491
 and 
PKD1 are altered in a pathological setting of T2D. To do so, we studied the db/db mouse 
model, which lacks the leptin receptor. To model the early stages of T2D, before many 
other complications are apparent, we sacrificed the mice after 4 consecutive weeks of 
significantly elevated fasting blood glucose levels (See Fig 6.7A) compared to db/+ 
controls, which was at 16 weeks of age. Body weights of db/db mice were significantly 
higher than db/+ controls at all timepoints measured (9-16 weeks of age) (Figure 6.7A). 
Phosphorylation of AMPK Ser
485/491
 was increased in liver but not gastrocnemius muscle 
of db/db mice compared to db/+ controls (Figure 6.7B, 6.7C). Similarly, p-PKD Ser
916
 
and phosphorylation of PKD substrates at 110kDa were increased in livers but not muscle 
of db/db mice. Somewhat surprisingly, phosphorylation of PKD substrates at 110kDa 
was diminished in the muscle of db/db mice, suggesting a decrease in PKD1 activity. 
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Figure 6.7: db/db mice have elevated p-AMPK Ser485/491 in liver compared to db/+ mice.  
Body weights and blood glucose levels of db/db and db/+ mice were measured every 
week starting at 9 weeks of age (A). Mice were sacrificed after 4 weeks of significantly 
elevated blood glucose levels between db/db and db/+. Gastrocnemius muscle and livers 
were homogenized and analyzed by western blot (B and C, respectively). AMPK serine 
phosphorylation was quantified by densitometry. Results are means ± SE (n = 5-7 per 
group). ∗p < 0.05 and ∗
 ∗ p < 0.001 indicates a significant effect of HF vs Control diet. (In 
collaboration with Jose Cacicedo and Rudy Valentine) 
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Discussion 
 The present studies investigated the physiological and pathological regulation of 
AMPK Ser
485/491
 phosphorylation as well as the regulation of the upstream kinases 
identified in chapters 4 and 5 to determine whether they are likely involved in the 
inhibition of AMPK in these settings. We showed in the previous chapter that PKD1 
activation and subsequent AMPK Ser
485/491 
phosphorylation impaired insulin signaling 
through Akt. Here, we investigate whether these mechanisms may be relevant in 
physiological and pathological settings of nutrient excess. 
 In the EDL incubated with high glucose, there were no significant increases in 
Akt phosphorylation, which is not surprising since the incubation medium did not contain 
insulin. However, there was a non-significant trend towards an increase in p-Akt Ser
473
 at 
1h, which could have contributed to the increase in serine phosphorylation of AMPK 
(Figure 6.1). In the muscle of glucose infused rats, which were hyperinsulinemic in 
addition to hyperglycemic, Akt phosphorylation was increased at all timepoints. In both 
models, activation of PKD1 was initially diminished before subsequently increasing to 
higher than control levels (Figure 6.4). The reason for the initial decrease requires further 
investigation, but the subsequent increase suggests that PKD1 may be responsible for the 
phosphorylation of AMPK Ser
485/491
 at later timepoints. Further evidence that PKD1 is 
involved is that pretreatment with the PKD1 inhibitor CRT0066101 prevented high 
glucose-induced phosphorylation of AMPK at Ser
485/491
 in the EDL (Figure 6.3). 
 Although Akt and PKD1 are likely involved in the phosphorylation and inhibition 
of AMPK in EDL incubated with high glucose, this does not rule out the possibility that 
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other kinases maybe also play a role. Since mTOR is known to be activated by high 
glucose [7] and its downstream effector P70S6K has been shown to phosphorylate 
AMPK at Ser
485/491
 [59], we evaluated whether the mTOR inhibitor rapamycin would 
prevent changes in AMPK phosphorylation in response to high glucose. Rapamycin did 
not prevent the decrease in p-AMPK Thr
172
, nor did it prevent the increase in p-AMPK 
Ser
485/491
, suggesting that mTOR/P70S6K is not acting upstream of AMPK in this setting 
(Figure 6.2). 
 Next, we sought to determine whether AMPK Ser
485/491
 and its upstream kinases 
were altered in physiological settings in response to feeding and pathological settings of 
obesity and T2D. Following an 18h fast, we found that p-AMPK Ser
485/491
 was increased 
in both gastrocnemius muscle and liver (Figure 6.6). We found that Akt phosphorylation 
was increased in both tissues, while PKD1 phosphorylation was only increased in liver. 
Why it was not also activated in muscle is not known, but perhaps it would be activated 
after a longer refeeding period. Interestingly, it was recently shown that PKD1 is 
activated in adipose tissue of mice fasted for 18h and refed for 2h [264]. Whether serine 
phosphorylation of AMPK is increased was not measured.  
 In the diabetic db/db mice, it was initially surprising that p-AMPK Ser
485/491
 was 
not increased, and PKD1 activation was also unchanged in the gastrocnemius muscle 
(Figure 6.7). However, these data fall in line with the hypothesis that PKD1 activation 
and, subsequently, AMPK Ser
485/491
 phosphorylation represent an anabolic cellular state. 
The muscles of db/db mice show atrophy since they are insulin resistant and thus, their 
uptake of glucose is impaired. On the other hand, the surplus of glucose and lipids 
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accumulates in the livers of db/db mice [265], which would lead to elevated DAG levels. 
As expected in this situation, we found increases in p-AMPK Ser
485/491
 and both p-PKD1 
Ser
916
 and phosphorylated PKD substrate at 110kDa. Based on these data, it is no surprise 
that PKD1 activation and p-AMPK Ser
485/491
 would be increased in states of nutrient 
excess (intracellularly), where DAG would signal through these molecules to inhibit 
catabolic processes in favor of anabolic processes such as hypertrophy. This mechanism 
seems particularly relevant to cardiac hypertrophy. PKD1 expression and 
phosphorylation are increased in rabbits and humans with heart failure (ischemic 
cardiomyopathy and idiopathic dilated cardiomyopathy) [222]. Mice lacking PKD1 in 
heart are protected from cardiac hypertrophy and fibrosis in response to pressure overload 
[223]. Furthermore, cardiac-specific overexpression of PKD1 triggers pathological 
hypertrophy in mice, suggesting that PKD1 is sufficient to cause cardiac remodeling 
[224]. Some studies have shown that AMPK activity is diminished in cardiac 
hypertrophy [266,267]; however, phosphorylation of Ser
485/491
 was not measured in these 
studies. Future studies should measure whether AMPK activity is diminished in cardiac 
hypertrophy via PKD1 phosphorylation of Ser
485/491
. If so, AMPK activators and/or 
PKD1 inhibitors could be novel strategies for the prevention or treatment of cardiac 
hypertrophy. 
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CHAPTER 7: Summary, Conclusions, and Future Directions 
Summary 
 In the present studies, we examined the effects of high glucose over time on 
AMPK activity and found that there are many mechanisms by which it is inhibited. In 
these studies, we compared rat muscle incubated with high glucose for 30min-2h and 
muscle of rats infused with glucose (3-8h) with appropriate controls. Incubation in high 
glucose (25mM) significantly diminished AMPK activity and phosphorylation at Thr
172
 
by 50% within 30min, with further decreases occurring at 1 and 2h. The initial decrease 
in activity at 30min coincided with a significant increase in muscle glycogen. The 
subsequent decreases at 1h were accompanied by phosphorylation of αAMPK at 
Ser
485/491
, and at 2h by decreased SIRT1 expression and increased PP2A activity, all of 
which have previously been shown to diminish AMPK activity. Glucose infusion in vivo, 
which caused several fold increases in plasma glucose and insulin, produced similar 
changes but with different timing. Thus, the initial decrease in AMPK activity observed 
at 3h was associated with changes in Ser
485/491 
phosphorylation and SIRT1 expression and 
increased PP2A activity was a later event. These findings suggest that both ex vivo and in 
vivo, multiple factors contribute to fuel-induced decreases in AMPK activity in skeletal 
muscle and the insulin resistance that accompanies it. 
 Recent studies suggest phosphorylation at Ser
485/491 
may play an important role in 
AMPK inhibition, although this has not been well studied in insulin-responsive tissues. 
Since it has previously been shown that insulin can inhibit AMPK via phosphorylation of 
Ser
485/491
 in heart and adipose tissue and because plasma insulin levels were significantly 
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increased in the glucose-infused rats, we investigated whether the insulin signaling 
pathway may be involved in regulating phosphorylation of this site in muscle. We found 
that insulin treatment significantly increased p-AMPK Ser
485/491 
in C2C12 myotubes and 
in ex vivo EDL incubation, resulting in a subsequent reduction in AMPK activity, despite 
no change in phosphorylation of AMPK at Thr
172
. Akt inhibition both attenuated the 
insulin-stimulated increase in p-AMPK Ser
485/491
, and prevented the decrease in AMPK 
activity. Similarly, the growth factor IGF-1 stimulated AMPK phosphorylation at 
Ser
485/491
, and this too was blunted by inhibition of Akt. Inhibition of the mTOR pathway 
with rapamycin, however, had no effect on insulin-stimulated phosphorylation of AMPK 
at Ser
485/491
. These data suggest that insulin and IGF-1 diminish AMPK activity in muscle 
through Akt-mediated phosphorylation at Ser
485/491
. 
 Since insulin was not present in the EDL incubation model in which we observed 
that high glucose stimulated phosphorylation of AMPK at Ser
485/491
, we investigated 
whether another kinase may be involved. Diacylglycerol (DAG), which is also increased 
in muscle exposed to a high glucose concentration, activates a number of signaling 
molecules including PKC and PKD. Thus, we sought to determine whether PKC or PKD 
is involved in inhibition of AMPK by causing Ser
485/491 
phosphorylation in skeletal 
muscle cells. C2C12 myotubes were treated with the PKC/D activator phorbol 12-
myristate 13-acetate (PMA), which acts as a DAG mimetic. This caused a dose- and 
time-dependent increase in AMPK Ser
485/491
 phosphorylation, which was associated with 
a ~60% decrease in AMPK activity. Under these conditions, serine phosphorylation and 
inhibition of AMPK activity were partially prevented by the non-specific PKC inhibitor 
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Gӧ6983 and fully prevented by specific PKD inhibition with CRT0066101. Inhibition of 
previously identified kinases that phosphorylate AMPK at this site (Akt, S6K, and ERK) 
did not prevent these events. PMA treatment also led to impairments in insulin signaling 
through Akt which were prevented by PKD inhibition. Recombinant PKD 
phosphorylated AMPK at Ser
485/491 
in cell-free conditions, suggesting that PKD 
phosphorylates and inhibits AMPK directly. We also found that PKD inhibition 
prevented AMPK Ser
485/491
 phosphorylation following incubation of EDL in high glucose 
for 2h. These results identify PKD as a novel upstream inhibitory kinase of AMPK 
Ser
485/491
 that plays a negative role in insulin signaling in muscle cells and intact muscle. 
 We next investigated how phosphorylation of AMPK at Ser
485/491
 is regulated 
under conditions of physiological and pathological nutrient excess. We found that p-
AMPK Ser
485/491
 was increased in muscle and liver of fed versus fasted mice. 
Additionally, we found that p-AMPK Ser
485/491
 was increased in the liver, but not muscle, 
of db/db diabetic mice. Our results suggest that Akt- and PKD1-mediated inhibition of 
AMPK via Ser
485/491
 phosphorylation may inhibit energy-metabolizing processes, while 
favoring energy-storing processes.  
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Figure 7.1: Overall proposed model 
We have shown that Akt and 
PKD, which are activated by 
insulin (and IGF-1) and DAG, 
respectively, can phosphorylate 
AMPK at Ser
485/491
 and 
subsequently inhibit its activity. 
When activated, AMPK 
stimulates catabolic processes, 
such as fatty acid oxidation, in 
order to restore cellular energy. 
Thus, we hypothesize that the 
phosphorylation of Ser
485/491
 is a 
regulatory mechanism to 
prevent AMPK-mediated 
catabolic processes, while 
allowing anabolic processes, 
such as growth and 
hypertrophy, to occur. Since 
insulin, IGF-1, and DAG are all increased in rodents and humans with the metabolic 
syndrome, phosphorylation of Ser
485/491
 may contribute to pathological inhibition of 
AMPK.  
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Conclusions 
 In the present studies, we have shown that exposure of muscle to high glucose, 
both ex vivo and in vivo, caused a progressive decrease in AMPK activity that was 
associated with changes in several factors that have all been shown to inhibit AMPK by 
various mechanism. An increase in muscle glycogen, which has been shown to inhibit 
AMPK by binding to its β-subunit, was the earliest observed change, which coincided 
with the diminished AMPK activity and phosphorylation at Thr
172
 at 30min. This was 
followed by subsequent changes in phosphorylation of Ser
485/491
 at 1h and diminished 
SIRT1 expression and increased PP2A activity at 2h, which were accompanied by further 
decreases in AMPK activity. These data suggest that glycogen may be responsible for the 
initial decrease in AMPK activity, while the other factors may contribute to its sustained 
inhibition, which may lead to more pathological changes in cellular metabolism. 
Furthermore, the changes in multiple factors that may regulate AMPK activity over time 
highlight a biological need to maintain tight control over AMPK enzyme activity. 
 In subsequent studies, we focused on the role and regulation of phosphorylation 
of AMPK at Ser
485/491
. Previous studies had shown it to be an important inhibitor of 
AMPK activity in various tissues, but its significance in insulin sensitive tissues, such as 
skeletal muscle, had not been investigated. Our findings add to a growing body of 
literature showing that phosphorylation at Ser
485/491 
is an important negative modulator of 
AMPK activity. Importantly, they highlight the fact that phosphorylation of Ser
485/491 
can 
inhibit AMPK activity independent of changes in p-AMPK Thr
172
, a measure which is 
often used as a readout of AMPK activity.  
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 We have shown that AMPK Ser
485/491
 was phosphorylated by Akt in response to 
insulin signaling and by PKD1 downstream of DAG. We also found that PKD1 mediated 
phosphorylation of Ser
485/491 
was associated with impaired insulin signaling, which was 
restored by PKD1 inhibition. We hypothesize that Akt-mediated inhibition of AMPK is 
an acute, physiological response to insulin, whereas PKD1-mediated inhibition may be 
associated with more chronic pathophysiological changes. Thus, PKD1 inhibition or 
prevention of Ser
485/491
 phosphorylation may represent new strategies for therapeutic 
AMPK activation as treatment for the metabolic syndrome.  
 We also found that p-AMPK Ser
485/491
 was increased in muscle and liver of fed vs 
fasted mice, and in liver, but not muscle, of db/db mice. Although the reason for the 
absence of changes in Ser
485/491
 phosphorylation in the muscle of db/db mice is unknown, 
it may be due to the timing which was used in this study. All other models in which we 
observed changes in Ser
485/491
 phosphorylation in muscle (ex vivo incubation, in vivo 
glucose infusion, and fasting/refeeding) represent early timepoints in the development of 
insulin resistance, whereas the db/db mice represent a later timepoint at which full on 
diabetes has developed. Thus, increased AMPK Ser
485/491 
phosphorylation may be an 
early event associated with the development of insulin resistance, but is not present later 
in diabetes when severe insulin resistance prevents the accumulation of DAG in muscle. 
In this case, it may not be a viable treatment strategy for insulin resistance in skeletal 
muscle, but could potentially hold promise as a prevention strategy. In contrast, the fact 
that we saw increased p-AMPK Ser
485/491
 and PKD1 activation in the liver of db/db mice 
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suggests that these may viable targets for treatment of insulin resistance in liver, which is 
another important insulin-responsive tissue. 
 As the T2D epidemic continues to grow, the need for safe and efficacious anti-
diabetic medications also increases. Current therapies leave much room for improvement, 
as most patients require multiple medications to get their blood glucose levels under 
control, and T2D is the 7
th
 leading cause of death in the US [268]. AMPK is an attractive 
target for T2D therapies because its activation stimulates a number of catabolic processes 
that are beneficial in the setting of diabetes, such as glucose uptake and fatty acid 
oxidation. The present studies have further elucidated the mechanisms by which AMPK 
is inhbited in response to excess nutrients. We have shown, for the first time, that 
phosphorylation of AMPK at Ser
485/491
 is an important negative modulator of AMPK 
activity in skeletal muscle and that Akt and PKD1 can inhibit AMPK by phosphorylation 
at this site. Further characterization of these and other upstream kinases of this site is 
required to determine whether inhibition of these kinases could be viable strategies for 
the treatment or prevention of insulin resistance. Due to other known functions of these 
proteins, this would likely have to be approached in a highly controlled, tissue specific 
manner. A treatment that could prevent the phosphorylation of AMPK at Ser
485/491
 
directly could potentially hold more promise as a therapeutic strategy.  
 
Future Directions  
 We have shown that exposure to excess glucose causes decreases in AMPK 
activity over time, along with sequential changes in a number of factors that may regulate 
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its activity. We hypothesize that the early changes, such as increased muscle glycogen 
content, may be more easily reversible, while later changes, such as the decrease in 
SIRT1 expression, may represent more pathological changes that are less reversible and 
may be associated with alterations in gene expression. To assess these hypotheses, studies 
should be carried out to evaluate the reversibility of the decrease in AMPK activity and 
the changes in its regulatory factors. This could be done in both the ex vivo muscle 
incubation model, where EDL could be incubated in 25mM glucose for various time 
periods followed by incubation in 5.5mM glucose, and the in vivo model of glucose 
infusion, where rats could be infused with glucose for various periods of time followed 
by restoration of normal glucose levels. These experiments would determine whether 
AMPK activity and its putative regulators return to control levels, and if so, how long it 
takes for this to occur. Additionally, studies could be done in which changes in each of 
the various factors associated with the decrease in AMPK activity are inhibited or 
prevented individually to determine the contribution of each factor to AMPK inhibition. 
For example, glycogen synthesis could be prevented by knocking down glycogen 
synthase, and PP2A activation could be prevented by treatment with okadaic acid. 
 We have shown that phosphorylation of AMPK at Ser
485/491 
is a negative 
modulator of AMPK activity. However, further studies are required to elucidate the 
effects of this inhibitory event on cellular functions, such as glucose uptake. Also still 
unanswered is whether inhibition of AMPK via phosphorylation at Ser
485/491 
differs from 
inhibition via the dephosphorylation at Thr
172
. Studies using phosphomimetic 
(S485/491A) and phosphodefective (S485/491D) mutants of AMPK could help 
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determine the specific effects of serine phosphorylation of AMPK on cellular functions. 
Measurements of glucose uptake, glycogen synthesis, and fatty acid oxidation are some 
cellular activities that may be affected. To build upon the studies performed here, in 
which pharmacological inhibitors of Akt and PKD1 were used to elucidate their role in 
the inhibition of AMPK, genetic methods should also be used to further confirm these 
findings. Specifically, siRNA knockdown of Akt and PKD1 should be done to determine 
whether phosphorylation of AMPK at Ser
485/491
 is prevented in response to insulin, PMA, 
and high glucose, and whether this completely prevents the inhibition of AMPK activity. 
Studies in which these enzymes are overexpressed would also be beneficial to determine 
whether this causes constitutive inhibition of AMPK and whether it mimics the effects of 
insulin, PMA, and high glucose.  
 Another future direction of this work would be to test whether currently available 
diabetes drugs and AMPK activators affect the phosphorylation of AMPK at Ser
485/491
. 
Although currently used therapies, such as metformin and thiazolidinediones (TZDs) are 
known to activate AMPK, whether AMPK activation is crucial to their insulin-sensitizing 
and glucose-lowering effects remains under debate. Determining whether these 
compounds affect AMPK phosphorylation at Ser
485/491
 could help define their 
mechanisms of action. Furthermore, if inhibition of Ser
485/491
 phosphorylation is 
determined to play an important role in the efficacy of these compounds, then compounds 
with this same property could be sought as novel therapeutics but perhaps with less side 
effects. 
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 Further characterization of the regulation of AMPK Ser
485/491 
phosphorylation in 
various physiological and pathological settings should be done to evaluate it as a target 
for pharmacological intervention. Here, we have examined its regulation in the muscle 
and liver of db/db mice at 16 weeks of age. At this age, these mice had significantly 
elevated fasting blood glucose levels for four consecutive weeks. However, at different 
ages and earlier or later stages in diabetes, the phosphorylation status of AMPK at 
Ser
485/491
 may be different and should be investigated. Additionally, other models of 
obesity and diabetes may show differences in the regulation of AMPK phosphorylation 
and activity. For example, rodents fed a high fat diet for 20 weeks have diminished 
phosphorylation of AMPK at Thr
172
 in muscle [269]; however, the effects of high fat 
feeding on the inhibitory phosphorylation of AMPK at Ser
485/491
 has not yet been studied. 
Whether AMPK activity is altered due to more or less inhibitory phosphorylation in 
PKD1 and Akt knockout and transgenic animals should also be evaluated. 
 In addition to insulin resistance and diabetes, the results of our studies may be 
relevant in other disease areas. PKD1 activity and expression have been shown to be 
increased in numerous models of cardiac hypertrophy and in some cancers, such as 
pancreatic cancer. Interestingly, some studies have shown that AMPK activity is 
diminished in cardiac hypertrophy and certain cancers and that AMPK activation could 
be a beneficial treatment for these conditions. Future studies should investigate whether 
AMPK Ser
485/491 
phosphorylation is increased in these conditions. These may represent 
new therapeutic indications where AMPK activation can be used as a treatment strategy. 
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